Subsidiary_NN
and_CC
associated_VBN
undertakings_GER
Principal_NN
subsidiary_NN
undertakings_GER
The_DT
information_NOMZ
provided_VBN [WZPAST]
below_PLACE
is_VPRT [PASS]
given_VBN
for_PIN
principal_JJ
subsidiary_NN
undertakings_GER
in_PIN
accordance_NN
with_PIN
Section_NOMZ
231_CD
5_CD
a_DT
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
A_DT
full_JJ
list_NN
will_PRMD
be_VB [PASS]
appended_VBN
to_PIN
the_DT
companys_NN
next_JJ
annual_JJ
return_NN
._.
Country_NN
of_PIN
operation_NOMZ
Activity_NOMZ
and_CC
incorporation_JJ
%_NN
owned_VBN
United_NN
Kingdom_NN
Smith_NN
&_CC
Nephew_NN
Healthcare_NN
Limited_NN
Medical_NN
devices_NN
United_NN
Kingdom_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
Medical_NN
Limited_NN
Medical_NN
devices_NN
United_NN
Kingdom_NN
100_CD
%_NN
TJ_NN
Smith_NN
&_CC
Nephew_NN
Limited_NN
Medical_NN
devices_NN
United_NN
Kingdom_NN
100_CD
%_NN
Continental_NN
Europe_NN
Smith_NN
&_CC
Nephew_NN
GmbH_NN
Medical_NN
devices_NN
Austria_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
SA-NV_NN
Medical_NN
devices_NN
Belgium_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
A_NN
S_NN
Medical_NN
devices_NN
Denmark_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
OY_NN
Medical_NN
devices_NN
Finland_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
SA_NN
Medical_NN
devices_NN
France_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
GmbH_NN
Medical_NN
devices_NN
Germany_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
Limited_NN
Medical_NN
devices_NN
Ireland_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
Srl_NN
Medical_NN
devices_NN
Italy_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
BV_NN
Medical_NN
devices_NN
Netherlands_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
A_NN
S_NN
Medical_NN
devices_NN
Norway_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
Lda_NN
Medical_NN
devices_NN
Portugal_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
SA_NN
Medical_NN
devices_NN
Spain_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
AB_NN
Medical_NN
devices_NN
Sweden_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
AG_NN
Medical_NN
devices_NN
Switzerland_NN
100_CD
%_NN
America_NN
Smith_NN
&_CC
Nephew_NN
Inc_NN
Medical_NN
devices_NN
Canada_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
SA_NN
fide_VBD
CV_NN
Medical_NN
devices_NN
Mexico_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
Inc_NN
Medical_NN
devices_NN
Puerto_NN
Rico_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
Inc_NN
Medical_NN
devices_NN
United_NN
States_NN
100_CD
%_NN
Africa_NN
,_,
Asia_NN
and_PHC
Australasia_NN
Smith_NN
&_CC
Nephew_NN
Pty_NN
Limited_NN
Medical_NN
devices_NN
Australia_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
Limited_NN
Medical_NN
devices_NN
Hong_NN
Kong_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
Healthcare_NN
Limited_NN
Medical_NN
devices_NN
India_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
KK_NN
Medical_NN
devices_NN
Japan_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
Limited_NN
Medical_NN
devices_NN
Korea_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
Healthcare_NN
Sdn_NN
Berhad_NN
Medical_NN
devices_NN
Malaysia_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
Limited_NN
Medical_NN
devices_NN
New_NN
Zealand_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
Pte_NN
Limited_NN
Medical_NN
devices_NN
Singapore_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
Limited_NN
Medical_NN
devices_NN
South_NN
Africa_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
Limited_NN
Medical_NN
devices_NN
Thailand_NN
100_CD
%_NN
Smith_NN
&_CC
Nephew_NN
FZE_NN
Medical_NN
devices_NN
United_NN
Arab_NN
Emirates_NN
100_CD
%_NN
Owned_VBN [WZPAST]
indirectly_RB
by_PIN
the_DT
parent_NN
company_NN
Principal_NN
associated_VBN
undertakings_GER
,_,
joint_JJ
ventures_NN
and_CC
other_JJ
arrangements_NOMZ
The_DT
group_NN
owns_VPRT
50_CD
%_NN
of_PIN
BSN_NN
Medical_NN
GmbH_NN
&_CC
Co_NN
KG_NN
,_,
a_DT
medical_JJ
devices_NN
company_NN
,_,
incorporated_VBN [PASTP]
in_PIN
Germany_NN
which_WDT [WHSUB]
has_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
the_DT
consolidated_JJ
accounts_NN
as_IN
a_DT
joint_JJ
venture_NN
._.
The_DT
group_NN
owns_VPRT
21.5_CD
%_NN
of_PIN
AbilityOne_NN
Corporation_NOMZ
,_,
a_DT
supplier_NN
of_PIN
rehabilitation_NOMZ
products_NN
to_PIN
hospitals_NN
,_,
nursing_VBG
homes_NN
and_PHC
clinics_NN
,_,
incorporated_VBN [PASTP]
in_PIN
the_DT
United_NN
States_NN
which_WDT [WHSUB]
has_VPRT [PEAS]
been_VBN [PASS]
included_VBN
in_PIN
the_DT
consolidated_JJ
accounts_NN
as_IN
an_DT
associated_VBN
undertaking_GER
._.
In_PIN
2001_CD
the_DT
group_NN
had_VBD
interests_NN
in_PIN
two_CD
joint_JJ
arrangements_NOMZ
with_PIN
Advanced_NN
Tissue_NN
Sciences_NN
,_,
Inc._NN
one_CD
relating_VBG
to_PIN
products_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
diabetic_JJ
foot_NN
ulcers_NN
and_CC
other_JJ
wound_NN
indications_NOMZ
,_,
and_ANDC
the_DT
other_JJ
for_PIN
cartilage_NN
replacement_NOMZ
._.
During_PIN
the_DT
year_NN
the_DT
group_NN
acquired_VBD
the_DT
interests_NN
it_PIT
did_VBD
not_XX0
already_RB
own_VB
in_PIN
the_DT
joint_JJ
arrangements_NOMZ
from_PIN
Advanced_NN
Tissue_NN
Sciences_NN
,_,
Inc._NN
52_CD
Smith_NN
&_CC
Nephew_NN
2002_CD
Information_NOMZ
for_PIN
shareholders_NN
Financial_JJ
calendar_NN
Shareview_NN
To_TO
view_VB
information_NOMZ
about_IN
your_SPP2
shareholdings_GER
on_PIN
the_DT
internet_NN
,_,
register_NN
at_PIN
www_NN
._.
com_NN
,_,
the_DT
Lloyds_NN
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
29_CD
April_NN
2003_CD
TSB_NN
enquiry_NN
and_PHC
portfolio_NN
management_NOMZ
service_NN
for_PIN
Payment_NOMZ
of_PIN
2002_CD
final_JJ
dividend_NN
16_CD
May_POMD
2003_CD
shareholders_NN
._.
When_RB
you_SPP2
have_VPRT [PEAS]
registered_VBN
for_PIN
shareview_NN
you_SPP2
Interim_VPRT
results_NN
announced_VBD [PUBV]
31_CD
July_NN
2003_CD
will_PRMD [SPAU]
also_RB
be_VB [BEMA]
able_PRED
to_TO
register_VB
your_SPP2
proxy_NN
instructions_NOMZ
online_VPRT
Payment_NOMZ
of_PIN
2003_CD
interim_JJ
dividend_NN
14_CD
November_NN
2003_CD
and_CC
elect_VB
to_TO
receive_VB
future_JJ
shareholder_NN
communications_NOMZ
Full_NN
year_NN
results_NN
announced_VBD [PUBV]
early_TIME
February_NN
2004_CD
via_PIN
our_FPP1
website_JJ
www_NN
._.
Annual_JJ
report_NN
posted_VBD
early_TIME
March_NN
2004_CD
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
5_CD
May_POMD
2004_CD
Shareholder_NN
Enquiries_NN
For_PIN
information_NOMZ
about_IN
the_DT
AGM_NN
,_,
shareholdings_GER
,_,
dividends_NN
and_PHC
changes_NN
to_PIN
personal_JJ
details_NN
Final_JJ
dividend_NN
all_QUAN
shareholders_NN
should_NEMD
contact_VB
:_:
Lloyds_NN
TSB_NN
Registrars_NN
,_,
The_DT
ordinary_JJ
shares_NN
will_PRMD
trade_VB
ex-dividend_NN
on_PIN
both_DT
the_DT
The_DT
Causeway_NN
,_,
Worthing_GER
,_,
West_NN
Sussex_NN
,_,
BN99_NN
6DS_NN
._.
London_NN
and_PHC
New_NN
York_NN
Stock_NN
Exchanges_NN
from_PIN
16_CD
April_NN
2003_CD
Telephone_NN
0870 600 3996_CD
._.
and_ANDC
the_DT
record_NN
date_NN
will_PRMD
be_VB [BEMA]
22_CD
April_NN
2003_CD
in_PIN
respect_NN
of_PIN
this_DEMO
years_NN
proposed_VBN [SUAV]
final_JJ
dividend_NN
to_TO
be_VB [PASS]
paid_VBN
on_PIN
16_CD
May_POMD
2003_CD
._.
American_JJ
depositary_NN
receipts_NN
ADRs_NN
In_PIN
the_DT
US_FPP1
,_,
the_DT
companys_NN
ordinary_JJ
shares_NN
are_VPRT [PASS]
traded_VBN
in_PIN
the_DT
Ordinary_NN
shares_NN
form_NN
of_PIN
American_JJ
Depositary_NN
Shares_NN
,_,
evidenced_VBN [PASTP]
by_PIN
ADRs_NN
,_,
Payment_NOMZ
of_PIN
cash_NN
dividends_NN
Shareholders_NN
who_WP [WHSUB]
wish_VPRT
their_TPP3
and_CC
trade_NN
under_IN
the_DT
symbol_NN
SNN_NN
._.
Each_QUAN
American_JJ
Depositary_NN
dividends_NN
to_TO
be_VB [PASS]
paid_VBN
directly_RB
to_PIN
a_DT
bank_NN
or_CC
building_GER
society_NN
Share_NN
represents_VPRT
ten_NN
ordinary_JJ
shares_NN
._.
Bank_NN
of_PIN
New_NN
York_NN
and_ANDC
who_WP
have_VPRT [PEAS]
not_XX0
already_RB
completed_VBN
a_DT
BACS_NN
mandate_NN
is_VPRT [BEMA]
the_DT
authorised_JJ
depositary_JJ
bank_NN
for_PIN
the_DT
companys_NN
ADR_NN
should_NEMD
contact_VB
the_DT
companys_NN
registrars_NN
._.
A_DT
Global_JJ
BuyDIRECT_NN
plan_NN
is_VPRT [BEMA]
available_PRED
for_PIN
US_FPP1
residents_NN
,_,
enabling_VBG
investment_NOMZ
directly_RB
in_PIN
ADRs_NN
with_PIN
Dividend_NN
re-investment_JJ
plan_NN
The_DT
company_NN
has_VPRT
a_DT
dividend_NN
reduced_VBN
brokerage_NN
commissions_NN
and_PHC
service_NN
costs_NN
._.
For_PIN
re-investment_JJ
plan_NN
that_TSUB
offers_VPRT
shareholders_NN
the_DT
opportunity_NOMZ
further_RB
information_NOMZ
on_PIN
Global_JJ
BuyDIRECT_NN
contact_NN
:_:
Bank_NN
to_TO
invest_VB
their_TPP3
cash_NN
dividends_NN
in_PIN
Smith_NN
&_CC
Nephew_NN
shares_NN
,_,
of_PIN
New_NN
York_NN
on_PIN
1-888-BNY-ADS_NN
toll-free_JJ
or_CC
visit_NN
which_WDT [WHSUB]
are_VPRT [PASS]
purchased_VBN
in_PIN
the_DT
market_NN
at_PIN
competitive_JJ
dealing_VBG
www_NN
._.
Application_NOMZ
forms_NN
for_PIN
re-investing_VBG
the_DT
2002_CD
final_JJ
dividend_NN
are_VPRT [BEMA]
available_PRED
from_PIN
Lloyds_NN
TSB_NN
Registrars_NN
who_WP [WHOBJ]
Smith_NN
&_CC
Nephew_NN
ADR_NN
price_NN
The_DT
companys_NN
ADR_NN
price_NN
is_VPRT
administer_VB
the_DT
plan_NN
on_PIN
behalf_NN
of_PIN
the_DT
company_NN
._.
Applications_NOMZ
quoted_VBD
daily_RB
in_PIN
the_DT
Wall_NN
Street_NN
Journal_NN
and_CC
can_POMD
be_VB [PASS]
obtained_VBN
for_PIN
re-investment_NOMZ
should_NEMD
be_VB [PASS]
returned_VBN
to_PIN
the_DT
companys_NN
from_PIN
the_DT
official_JJ
New_NN
York_NN
Stock_NN
Exchange_NN
website_JJ
registrars_NN
by_PIN
29_CD
April_NN
2003_CD
._.
www_NN
._.
UK_NN
capital_NN
gains_NN
tax_NN
For_PIN
the_DT
purposes_NN
of_PIN
capital_NN
gains_NN
tax_NN
ADR_NN
Enquiries_NN
All_QUAN
enquiries_NN
regarding_VBG [WZPRES]
ADR_NN
holder_NN
accounts_VPRT
the_DT
price_NN
of_PIN
ordinary_JJ
shares_NN
on_PIN
31_CD
March_NN
1982_CD
was_VBD [BEMA]
35.04_CD
p._NN
and_PHC
payment_NOMZ
of_PIN
dividends_NN
should_NEMD
be_VB [PASS]
addressed_VBN
to_PIN
Bank_NN
of_PIN
New_NN
York_NN
,_,
620_CD
Avenue_NN
of_PIN
the_DT
Americas_NN
,_,
New_NN
York_NN
,_,
Smith_NN
&_CC
Nephew_NN
share_NN
price_NN
The_DT
companys_NN
share_VPRT
price_NN
is_VPRT
New_NN
York_NN
10011_CD
._.
quoted_VBN
daily_JJ
in_PIN
national_JJ
newspapers_NN
,_,
as_RB
well_RB
as_IN
on_PIN
Ceefax_NN
and_PHC
Teletext_NN
and_CC
at_PIN
www_NN
._.
com_NN
where_RB
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
it_PIT
is_VPRT [PASS]
updated_VBN
at_PIN
intervals_NN
throughout_PIN
the_DT
day_NN
._.
The_DT
Financial_NN
The_DT
companys_NN
66th_VPRT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
is_VPRT
to_TO
be_VB [PASS]
held_VBN [PRIV]
Times_NN
Cityline_NN
Service_NN
,_,
telephone_NN
0906 0034043_CD
,_,
provides_VPRT
on_PIN
29_CD
April_NN
2003_CD
at_PIN
10.30_CD
am_VPRT [BEMA]
at_PIN
the_DT
Institute_NN
of_PIN
Mechanical_NN
an_DT
up_RB
to_PIN
the_DT
minute_JJ
share_NN
price_NN
._.
A_DT
fee_NN
is_VPRT [PASS]
charged_VBN
for_PIN
this_DEMO
Engineers_NN
,_,
One_CD
Birdcage_NN
Walk_VPRT
,_,
London_NN
,_,
SW1H_NN
9JJ_NN
._.
of_PIN
the_DT
meeting_GER
is_VPRT [PASS]
enclosed_VBN
with_PIN
an_DT
accompanying_JJ
letter_NN
from_PIN
the_DT
Chairman_NN
._.
Low-cost_JJ
dealing_VBG
service_NN
A_DT
postal_JJ
and_CC
telephone_NN
facility_NOMZ
that_TSUB
provides_VPRT
a_DT
simple_JJ
low-cost_JJ
method_NN
of_PIN
buying_NN
and_PHC
Registered_NN
office_NN
selling_GER
Smith_NN
&_CC
Nephew_NN
shares_NN
is_VPRT [BEMA]
available_PRED
through_PIN
Hoare_NN
Smith_NN
&_CC
Nephew_NN
plc_NN
,_,
15_CD
Adam_NN
Street_NN
,_,
Govett_NN
Limited_NN
._.
For_PIN
information_NOMZ
contact_NN
Hoare_NN
Govett_NN
London_NN
WC2N_NN
6LA_NN
Ltd._NN
250_CD
Bishopsgate_NN
,_,
London_NN
,_,
EC2M_NN
4AA_NN
._.
Telephone_NN
Registered_NN
in_PIN
England_NN
No._NN
._.
Advisers_NN
Smith_NN
&_CC
Nephew_NN
Corporate_NN
ISA_NN
The_DT
company_NN
has_VPRT
a_DT
Solicitors_NN
:_:
Ashurst_NN
Morris_NN
Crisp_NN
corporate_JJ
Individual_NN
Savings_GER
Account_NN
ISA_NN
administered_VBN [WZPAST]
by_PIN
Pinsent_NN
Curtis_NN
Biddle_NN
Lloyds_NN
TSB_NN
Registrars_NN
._.
For_PIN
information_NOMZ
about_IN
this_DEMO
service_NN
Auditors_NN
:_:
Ernst_NN
&_CC
Young_NN
LLP_NN
please_VB
contact_VB
their_TPP3
helpline_NN
on_PIN
telephone_NN
0870 2424 244_CD
._.
Stockbrokers_NN
:_:
Cazenove_NN
&_CC
Co_NN
Dresdner_NN
Kleinwort_NN
Wasserstein_NN
Trademarks_NN
The_DT
product_NN
names_NN
referred_VBD
to_PIN
in_PIN
this_DEMO
document_NOMZ
are_VPRT [BYPA]
trademarks_NN
owned_VBN [WZPAST]
by_PIN
or_CC
licensed_VBN
to_PIN
members_NN
of_PIN
the_DT
Smith_NN
&_CC
Nephew_NN
group_NN
._.
Designed_VBN
and_PHC
produced_VBN
by_PIN
Fitch_NN
:_:
London_NN
._.
Board_NN
photography_NN
by_PIN
Sven_NN
Seiffert_NN
._.
pp_NN
You_SPP2
have_VPRT
access_NN
to_PIN
more_EMPH
information_NOMZ
from_PIN
the_DT
following_JJ
sources_NN
:_:
Board_NN
Group_NN
Executive_NN
Committee_NN
biographies_NN
For_PIN
further_JJ
biographies_NN
,_,
visit_NN
:_:
www_NN
._.
html_NN
Presentations_NOMZ
For_PIN
presentations_NOMZ
to_PIN
analysts_NN
and_PHC
shareholders_NN
,_,
visit_NN
:_:
www_NN
._.
html_NN
You_SPP2
are_VPRT
here_RB
:_:
Annual_JJ
Report_NN
and_PHC
Accounts_NN
Contents_NN
Financial_NN
highlights_VPRT
Chairmans_NN
statement_NOMZ
Chief_NN
Executives_NN
statement_NOMZ
Board_NN
&_CC
Group_NN
Executive_NN
Committee_NN
Financial_NN
review_NN
Corporate_JJ
social_JJ
responsibility_NOMZ
Corporate_JJ
governance_NN
Remuneration_NOMZ
report_NN
Directors_NN
responsibilities_NOMZ
Auditors_NN
report_VPRT [PUBV]
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
Group_NN
balance_NN
sheet_NN
Group_NN
cash_NN
ow_NN
statement_NOMZ
Statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
Movement_NOMZ
in_PIN
shareholders_NN
funds_NN
Parent_NN
company_NN
balance_NN
sheet_NN
Accounting_GER
policies_NN
Notes_NN
to_PIN
the_DT
accounts_NN
Group_NN
five_CD
year_NN
summary_NN
Subsidiary_NN
and_CC
associated_VBN
undertakings_GER
Information_NOMZ
for_PIN
shareholders_NN
Available_JJ
as_IN
a_DT
printed_VBN
document_NOMZ
or_CC
online_NN
at_PIN
:_:
www_NN
._.
com_NN
investors_NN
annualreport2002_JJ
Sustainability_NOMZ
report_NN
For_PIN
further_JJ
information_NOMZ
on_PIN
sustainability_NOMZ
and_CC
to_TO
access_VB
our_FPP1
report_NN
,_,
visit_NN
:_:
www_NN
._.
com_NN
sustainability2002_CD
Shareholder_NN
information_NOMZ
For_PIN
further_JJ
up-to-date_JJ
shareholder_NN
information_NOMZ
,_,
visit_NN
:_:
www_NN
._.
html_NN
For_PIN
up-to-minute_JJ
share_NN
price_NN
information_NOMZ
,_,
visit_NN
:_:
www_NN
._.
com_NN
Smith_NN
&_CC
Nephew_NN
plc_NN
investors_NN
financial_JJ
data_NN
._.
html_NN
15_CD
Adam_NN
Street_NN
For_PIN
press_NN
releases_NN
and_CC
latest_JJ
business_NOMZ
information_NOMZ
,_,
visit_NN
:_:
London_NN
WC2N_NN
6LA_NN
www_NN
._.
com_NN
Delivering_GER
Sustainable_NN
Growth_NN
2002_CD
Report_NN
to_PIN
Shareholders_NN
and_PHC
Summary_NN
Financial_NN
Statement_NOMZ
Financial_NN
highlights_VPRT
2002_CD
2001_CD
million_CD
million_CD
Turnover_NN
1,109.9_CD
1,081.7_CD
Profit_NN
before_IN
taxation_NOMZ
:_:
before_IN
goodwill_NN
amortisation_NOMZ
and_CC
exceptional_JJ
items_NN
209.9_CD
180.9_CD
after_IN
goodwill_NN
amortisation_NOMZ
and_CC
exceptional_JJ
items_NN
177.9_CD
193.6_CD
Earnings_GER
per_PIN
share_NN
before_IN
goodwill_NN
amortisation_NOMZ
and_CC
exceptional_JJ
items_NN
16.02_CD
p_NN
13.96_CD
p_NN
Earnings_GER
per_PIN
share_NN
after_IN
goodwill_NN
amortisation_NOMZ
and_CC
exceptional_JJ
items_NN
12.11_CD
p_NN
14.07_CD
p_NN
Dividends_NN
per_PIN
share_NN
4.80_CD
p_NN
4.65_CD
p_NN
We_FPP1
are_VPRT [PASS]
committed_VBN
to_TO
setting_VBG
new_JJ
standards_NN
in_PIN
patient_JJ
treatment_NOMZ
and_PHC
recovery_NN
,_,
Contents_NN
Directors_NN
report_VPRT [PUBV]
01_CD
Financial_JJ
highlights_VPRT
02_CD
Chairmans_NN
statement_NOMZ
PERFORMANCE_NN
04_CD
Chief_NN
Executives_NN
statement_NOMZ
OUR_FPP1
PERFORMANCE_NN
CULTURE_NN
IS_VPRT [BEMA]
10_CD
Board_NN
&_CC
Group_NN
Executive_NN
Committee_NN
DRIVING_GER
GLOBAL_NN
SALES_NN
GROWTH_NN
12_CD
Corporate_JJ
social_JJ
responsibility_NOMZ
AND_PHC
MARGIN_NN
IMPROVEMENT_NOMZ
._.
14_CD
Corporate_JJ
governance_NN
15_CD
Summary_NN
remuneration_NOMZ
report_NN
Accounts_NN
16_CD
Auditors_NN
statement_NOMZ
17_CD
Summary_NN
financial_JJ
statement_NOMZ
19_CD
Information_NOMZ
for_PIN
shareholders_NN
20_CD
Group_NN
five_CD
year_NN
summary_NN
1,135_CD
17.8_CD
16.02_CD
1,120_CD
1,110_CD
17.1_CD
1,082_CD
1,053_CD
16.4_CD
13.96_CD
1,084_CD
15.1_CD
14.7_CD
978_CD
12.19_CD
912_CD
10.88_CD
800_CD
9.61_CD
714 1998 1999 2000_CD
2001 2002 1998 1999_CD
2000 2001 2002 1998_CD
1999 2000 2001 2002_CD
Group_NN
Turnover_NN
Group_NN
Margins_NN
%_NN
Earnings_GER
Per_PIN
Share_NN
Continuing_VBG [WZPRES]
Sales_NN
Before_IN
goodwill_NN
before_IN
goodwill_NN
Million_NN
amortisation_NOMZ
and_PHC
amortisation_NOMZ
and_CC
exceptional_JJ
Items_NN
exceptional_JJ
items_NN
Pence_NN
as_RB
well_RB
as_IN
delivering_VBG
on_PIN
our_FPP1
promise_NN
of_PIN
healthy_JJ
returns_NN
to_PIN
our_FPP1
shareholders_NN
._.
INNOVATION_NOMZ
OUR_FPP1
COMMERCIALLY_NN
ORIENTATED_NN
RESEARCH_NN
AND_PHC
DEVELOPMENT_NOMZ
IS_VPRT
CONTRIBUTING_GER
TO_PIN
A_DT
STRONG_NN
NEW_NN
PRODUCT_NN
PIPELINE_NN
._.
TRUST_NN
OUR_FPP1
SUSTAINABILITY_NOMZ
PROGRESS_NN
HAS_VPRT
BEEN_NN
RECOGNISED_NN
BY_PIN
OUR_FPP1
ENTRY_NN
INTO_PIN
THE_DT
DOW_NN
JONES_NN
SUSTAINABILITY_NOMZ
INDEX_NN
FOR_PIN
2003_CD
._.
Where_RB
this_DEMO
icon_NN
appears_VPRT [SMP]
,_,
more_EMPH
information_NOMZ
can_POMD
be_VB [PASS]
found_VBN [PRIV]
at_PIN
an_DT
alternative_JJ
source_NN
._.
For_PIN
more_EMPH
detailed_JJ
financial_JJ
information_NOMZ
visit_NN
www_NN
._.
html_NN
TriGen_NN
A_NN
summer_NN
time_NN
car_NN
crash_NN
landed_VBD
this_DEMO
universitybound_JJ
student_NN
on_PIN
a_DT
surgeons_NN
operating_VBG [WZPRES]
table_NN
with_PIN
a_DT
femoral_JJ
fracture_NN
._.
The_DT
less-invasive_JJ
TriGen_NN
femoral_JJ
nailing_GER
system_NN
helped_VBD
to_TO
mend_VB
her_TPP3
broken_JJ
bone_NN
and_CC
restored_VBD
her_TPP3
to_TO
walking_VBG
so_IN
she_TPP3
could_POMD
start_VB
the_DT
autumn_NN
term_NN
in_PIN
time_NN
._.
We_FPP1
have_VPRT [PEAS]
had_VBD
another_DT
excellent_JJ
year_NN
of_PIN
growth_NN
within_PIN
each_QUAN
of_PIN
our_FPP1
three_CD
businesses_NOMZ
._.
Financial_NN
performance_NN
and_PHC
dividend_NN
Chairmans_NN
Group_NN
sales_NN
grew_VBD
strongly_AMP
,_,
led_VBN [PASTP]
by_PIN
the_DT
Orthopaedics_NN
business_NOMZ
._.
Underlying_JJ
growth_NN
of_PIN
statement_NOMZ
14_CD
%_NN
was_VBD [BYPA]
augmented_VBN
by_PIN
acquisitions_NOMZ
,_,
which_WDT [SERE]
added_VBD [PUBV]
a_DT
further_JJ
4_CD
%_NN
._.
Our_FPP1
drive_NN
to_TO
deliver_VB
innovative_JJ
products_NN
across_PLACE
all_QUAN
our_FPP1
businesses_NOMZ
is_VPRT
paying_VBG
off_PIN
In_PIN
2002_CD
we_FPP1
achieved_VBD
our_FPP1
targets_NN
within_PIN
the_DT
and_CC
we_FPP1
are_VPRT [SPAU]
also_RB
benefiting_VBG
from_PIN
the_DT
past_JJ
two_CD
Orthopaedics_NN
,_,
Endoscopy_NN
and_PHC
Advanced_NN
years_NN
sales_NN
force_NN
expansions_NN
._.
Each_QUAN
of_PIN
Smith_NN
&_CC
Nephews_NN
businesses_NOMZ
strengthened_VBD
its_PIT
We_FPP1
achieved_VBD
an_DT
ongoing_JJ
operating_GER
margin_NN
positions_NOMZ
in_PIN
the_DT
markets_NN
in_PIN
which_WDT [PIRE]
it_PIT
operates_VPRT
before_IN
exceptional_JJ
items_NN
of_PIN
16.5_CD
%_NN
,_,
despite_PIN
the_DT
through_PIN
a_DT
combination_NOMZ
of_PIN
sales_NN
growth_NN
,_,
new_JJ
dissynergies_NN
of_PIN
the_DT
restructuring_GER
divestments_VPRT
products_NN
and_PHC
technology_NN
acquisition_NOMZ
._.
The_DT
underlying_VBG
margin_NN
increased_VBN [WZPAST]
by_PIN
0.7_CD
%_NN
._.
Before_IN
goodwill_NN
amortisation_NOMZ
,_,
In_PIN
March_NN
2002_CD
we_FPP1
acquired_VBD
and_PHC
have_VPRT
since_OSUB
the_DT
margin_NN
was_VBD [BEMA]
18.1_CD
%_NN
._.
successfully_RB
integrated_VBN
ORATEC_NN
Interventions_NOMZ
,_,
Inc._NN
establishing_VBG [PRIV] [WZPRES]
our_FPP1
Endoscopy_JJ
business_NOMZ
as_IN
Investors_NN
continue_VPRT
to_TO
recognize_VB [PRIV]
the_DT
companys_NN
a_DT
leader_NN
in_PIN
radiofrequency_NN
technology_NN
and_PHC
strength_NN
and_PHC
share_NN
price_NN
growth_NN
potential_NN
._.
Smith_NN
minimally_RB
invasive_JJ
spinal_JJ
surgery_NN
._.
We_FPP1
also_RB
&_CC
Nephew_NN
was_VBD [BEMA]
one_CD
of_PIN
the_DT
UKs_NN
best-performing_JJ
acquired_VBD
the_DT
remaining_VBG
half_NN
of_PIN
the_DT
Dermagraft_NN
stocks_NN
in_PIN
2002_CD
,_,
outperforming_VBG [PRESP]
the_DT
FTSE_NN
100_CD
by_PIN
and_CC
TransCyte_NN
joint_JJ
arrangements_NOMZ
from_PIN
more_EMPH
than_PIN
20_CD
%_NN
._.
The_DT
recommended_VBN [SUAV]
final_JJ
dividend_NN
Advanced_NN
Tissue_NN
Sciences_NN
,_,
Inc._NN
gaining_VBG [WZPRES]
full_JJ
is_VPRT [PASS]
increased_VBN
to_PIN
3.00_CD
p_NN
,_,
making_VBG [PRESP]
a_DT
total_JJ
dividend_NN
strategic_JJ
control_NN
of_PIN
those_DEMO
products_NN
._.
We_FPP1
disposed_VBD
of_PIN
our_FPP1
Rehabilitation_NOMZ
business_NOMZ
People_NN
to_PIN
AbilityOne_NN
Corporation_NOMZ
also_RB
in_PIN
March_NN
2002_CD
,_,
Our_FPP1
people_NN
take_VPRT
pride_NN
in_PIN
our_FPP1
products_NN
which_WDT [WHSUB]
retaining_VBG
a_DT
21.5_CD
%_NN
interest_NN
in_PIN
the_DT
expanded_VBN
enable_VPRT
patients_NN
to_TO
regain_VB
their_TPP3
lives_NN
._.
This_DEMP
focused_VBD
the_DT
group_NN
on_PIN
our_FPP1
three_CD
extremely_AMP
talented_JJ
group_NN
of_PIN
individuals_NN
and_CC
we_FPP1
chosen_VBN
areas_NN
of_PIN
expertise_NN
._.
thank_VB
them_TPP3
for_PIN
their_TPP3
commitment_NOMZ
,_,
creativity_NOMZ
and_PHC
energy_NN
in_PIN
serving_VBG
the_DT
company_NN
and_CC
the_DT
medical_JJ
community_NOMZ
._.
02_CD
Smith_NN
&_CC
Nephew_NN
2002_CD
TriVex_NN
procedure_NN
Dermagraft_NN
She_TPP3
faces_VPRT
the_DT
same_JJ
A_DT
keen_JJ
golfer_NN
,_,
he_TPP3
has_VPRT
problems_NN
every_QUAN
mother_NN
suffered_VBD
from_PIN
diabetes_NN
does_VPRT
:_:
dressing_VBG [PRESP]
the_DT
kids_NN
,_,
all_QUAN
his_TPP3
life_NN
._.
He_TPP3
ignored_VBD
making_VBG
lunches_NN
,_,
finding_VBG [PRIV] [PRESP]
a_DT
wound_NN
on_PIN
his_TPP3
foot_NN
,_,
time_NN
for_PIN
herself_TPP3
._.
Faced_VBN
thinking_VBG [PRIV] [THATD]
it_PIT
would_PRMD
clear_VB
with_PIN
an_DT
uphill_PLACE
battle_NN
of_PIN
up_RB
,_,
but_CC
when_RB
he_TPP3
lost_VBD
another_DT
type_NN
one_CD
sensation_NOMZ
in_PIN
his_TPP3
lower_JJ
against_PIN
unsightly_JJ
,_,
painful_JJ
leg_NN
he_TPP3
finally_RB
went_VBD
to_TO
see_VB [PRIV]
varicose_JJ
veins_NN
,_,
she_TPP3
his_TPP3
doctor_NN
._.
The_DT
foot_NN
ulcer_NN
received_VBD
treatment_NOMZ
with_PIN
was_VBD [BEMA]
so_EMPH
serious_PRED
he_TPP3
was_VBD [BEMA]
the_DT
TriVex_NN
procedure_NN
._.
in_PIN
real_JJ
danger_NN
of_PIN
having_VBG
She_TPP3
can_POMD [SPAU]
now_TIME
handle_VB
the_DT
limb_NN
amputated_VBD
._.
the_DT
challenges_NN
of_PIN
After_IN
12_CD
weeks_NN
of_PIN
being_VBG [PASS]
motherhood_VBN
without_PIN
the_DT
treated_VBN
with_PIN
Dermagraft_NN
,_,
added_VBD [PUBV]
difficulty_NN
of_PIN
leg_NN
a_DT
bio-engineered_JJ
human_JJ
pain_NN
,_,
which_WDT [SERE]
allows_VPRT [SUAV]
her_TPP3
dermal_JJ
replacement_NOMZ
,_,
more_EMPH
time_NN
to_TO
concentrate_VB
he_TPP3
was_VBD [BEMA]
out_PIN
of_PIN
the_DT
danger_NN
on_PIN
what_WP
matters_VPRT
most_EMPH
zone_NN
and_CC
looking_VBG
forward_RB
her_TPP3
family_NN
._.
We_FPP1
remain_VPRT
confident_JJ
in_PIN
our_FPP1
ability_NOMZ
to_TO
deliver_VB
sustainable_JJ
growth_NN
for_PIN
the_DT
future_NN
._.
We_FPP1
pay_VPRT
particular_JJ
tribute_NN
to_PIN
Larry_NN
Papasan_NN
markets_NN
._.
In_PIN
2003_CD
,_,
we_FPP1
will_PRMD
see_VB [PRIV]
the_DT
impact_NN
of_PIN
for_PIN
his_TPP3
valued_VBN
contribution_NOMZ
as_IN
President_NN
of_PIN
the_DT
our_FPP1
strong_JJ
ongoing_JJ
sales_NN
and_PHC
profit_NN
growth_NN
Orthopaedics_NN
business_NOMZ
._.
He_TPP3
retired_VBD
at_PIN
the_DT
end_NN
on_PIN
our_FPP1
reported_VBN [PUBV]
results_NN
without_PIN
the_DT
impact_NN
of_PIN
2002_CD
and_CC
we_FPP1
welcome_VPRT
David_NN
Illingworth_NN
,_,
of_PIN
divestments_NOMZ
._.
who_WP
has_VPRT [PEAS]
joined_VBN
us_FPP1
to_TO
lead_VB
the_DT
division_NN
to_PIN
further_JJ
success_NN
._.
We_FPP1
have_VPRT
a_DT
leading_JJ
range_NN
of_PIN
technology_NN
and_PHC
products_NN
that_TSUB
repair_VPRT
and_PHC
heal_VPRT
the_DT
human_JJ
body_NN
._.
Board_NN
We_FPP1
will_PRMD
maintain_VB [PUBV]
our_FPP1
progress_NN
by_PIN
investing_VBG
in_PIN
Tim_NN
Lankester_NN
has_VPRT [PEAS]
chosen_VBN
not_XX0
to_TO
stand_VB
again_TIME
new_JJ
and_PHC
differentiated_JJ
technologies_NN
which_WDT [WHSUB]
bring_VPRT
for_PIN
re-election_NOMZ
to_PIN
the_DT
Board_NN
and_CC
will_PRMD
be_VB
standing_VBG
benefits_NN
to_PIN
patients_NN
,_,
and_ANDC
in_PIN
the_DT
specialist_NN
sales_NN
down_RB
at_PIN
the_DT
AGM_NN
in_PIN
April_NN
._.
We_FPP1
thank_VPRT
him_TPP3
for_PIN
forces_NN
to_TO
bring_VB
these_DEMO
products_NN
to_PIN
the_DT
medical_JJ
his_TPP3
contribution_NOMZ
over_IN
the_DT
last_JJ
seven_CD
years_NN
._.
We_FPP1
will_PRMD
continue_VB
to_TO
invest_VB
in_PIN
our_FPP1
businesses_NOMZ
by_PIN
increasing_VBG
sales_NN
force_NN
strength_NN
,_,
Corporate_JJ
governance_NN
has_VPRT [PEAS]
been_VBN [BEMA]
a_DT
priority_NOMZ
adding_VBG [PUBV] [WZPRES]
manufacturing_GER
capacity_NOMZ
and_CC
enhancing_VBG
over_IN
the_DT
past_JJ
year_NN
particularly_RB
as_IN
we_FPP1
are_VPRT [PASS]
listed_VBN
new_JJ
product_NN
development_NOMZ
to_TO
generate_VB
vigorous_JJ
on_PIN
both_DT
the_DT
London_NN
and_PHC
New_NN
York_NN
Stock_NN
growth_NN
._.
We_FPP1
will_PRMD [SPAU]
also_RB
acquire_VB
businesses_NOMZ
or_CC
Exchanges_NN
._.
Smith_NN
&_CC
Nephew_NN
is_VPRT [PASS]
committed_VBN
to_PIN
technologies_NN
that_TSUB
strengthen_VPRT
our_FPP1
long_JJ
term_NN
an_DT
open_JJ
and_PHC
constructive_JJ
relationship_NN
with_PIN
our_FPP1
prospects_NN
._.
shareholders_NN
and_CC
the_DT
overall_JJ
investment_NOMZ
community_NOMZ
._.
We_FPP1
are_VPRT
working_VBG
to_TO
comply_VB
with_PIN
the_DT
We_FPP1
remain_VPRT
confident_JJ
of_PIN
delivering_VBG
sustainable_JJ
new_JJ
US_FPP1
Sarbanes-Oxley_NN
Act_NN
and_CC
the_DT
ongoing_JJ
growth_NN
and_CC
believe_VB [PRIV] [THATD]
we_FPP1
are_VPRT [SPAU] [PASS]
well_RB
placed_VBN
to_TO
detailed_VBN
guidelines_NN
being_VBG [WZPRES] [BYPA]
supplied_VBN
by_PIN
the_DT
achieve_VB
our_FPP1
mid-teens_NN
underlying_VBG [WZPRES]
pre-goodwill_JJ
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
._.
amortisation_NOMZ
EPS_NN
growth_NN
target_NN
going_VBG [WZPRES]
forward_RB
._.
Outlook_NN
The_DT
markets_NN
on_PIN
which_WDT [PIRE]
we_FPP1
focus_VPRT
continue_VB
to_TO
demonstrate_VB [PRIV]
robust_JJ
growth_NN
._.
Smith_NN
&_CC
Nephew_NN
is_VPRT
achieving_VBG
sales_NN
growth_NN
that_TSUB
outpaces_VPRT
the_DT
industry_NN
,_,
and_ANDC
is_VPRT
demonstrating_VBG [PRIV]
its_PIT
ability_NOMZ
to_TO
grow_VB
share_NN
and_PHC
position_NOMZ
within_PIN
the_DT
Orthopaedics_NN
,_,
Dudley_NN
Eustace_NN
Endoscopy_NN
and_PHC
Advanced_NN
Wound_NN
Management_NOMZ
Chairman_NN
Smith_NN
&_CC
Nephew_NN
2002_CD
03_CD
Product_NN
markets_NN
%_NN
Geographic_JJ
markets_NN
%_NN
sales_NN
from_PIN
ongoing_JJ
operations_NOMZ
sales_NN
from_PIN
ongoing_JJ
operations_NOMZ
UK_NN
8_CD
%_NN
Advanced_NN
wound_VBD
Africa_NN
,_,
Asia_NN
&_CC
management_NOMZ
30_CD
%_NN
Australasia_NN
14_CD
%_NN
Orthopaedics_NN
43_CD
%_NN
Continental_NN
Europe_NN
22_CD
%_NN
Endoscopy_NN
27_CD
%_NN
America_NN
56_CD
%_NN
Our_FPP1
new_JJ
products_NN
are_VPRT
driving_VBG
our_FPP1
growth_NN
and_CC
setting_VBG
new_JJ
standards_NN
of_PIN
care_NN
._.
Market_NN
growth_NN
remains_VPRT
buoyant_JJ
and_CC
Chief_NN
Executives_NN
demographics_NN
and_PHC
lifestyle_NN
trends_NN
remain_VPRT
positive_JJ
._.
Healthcare_NN
expenditure_NN
continues_VPRT
to_TO
grow_VB
in_PIN
all_QUAN
statement_NOMZ
our_FPP1
major_JJ
markets_NN
._.
Technology_NN
is_VPRT
expanding_VBG
the_DT
marketplace_NN
through_PIN
the_DT
growth_NN
of_PIN
less_JJ
invasive_JJ
and_CC
longer_RB
lasting_JJ
surgical_JJ
techniques_NN
and_CC
Delivering_VBG
sustainable_JJ
growth_NN
implants_NN
._.
With_PIN
the_DT
introduction_NOMZ
of_PIN
new_JJ
orthopaedic_JJ
In_PIN
2002_CD
our_FPP1
markets_NN
grew_VBD
strongly_AMP
and_PHC
once_TIME
bearing_VBG
materials_NN
,_,
led_VBN [PASTP]
by_PIN
Oxinium_NN
from_PIN
Smith_NN
&_CC
again_TIME
Smith_NN
&_CC
Nephew_NN
outpaced_VBD
the_DT
industry_NN
._.
Nephew_NN
,_,
surgeons_NN
are_VPRT [SPAU]
increasingly_RB
treating_VBG
I_FPP1
am_VPRT [BEMA]
pleased_PRED
to_TO
report_VB [PUBV]
excellent_JJ
growth_NN
in_PIN
our_FPP1
younger_JJ
patient_JJ
groups_NN
._.
New_NN
techniques_NN
Orthopaedics_NN
,_,
Endoscopy_NN
and_PHC
Advanced_NN
Wound_VBD
continue_VB
to_TO
simplify_VB
and_PHC
make_VB
procedures_NN
faster_RB
,_,
Management_NOMZ
businesses_NOMZ
._.
and_ANDC
less_RB
invasive_JJ
techniques_NN
in_PIN
orthopaedics_NN
and_CC
endoscopy_JJ
are_VPRT
taking_VBG
hold_NN
as_IN
patients_NN
increasingly_RB
We_FPP1
now_TIME
have_VPRT
formidable_JJ
teams_NN
in_PIN
place_NN
and_PHC
drive_NN
demand_NN
._.
Technology_NN
advancements_NOMZ
in_PIN
we_FPP1
are_VPRT [PASS]
focused_VBN
on_PIN
three_CD
high-growth_NN
markets_NN
._.
treating_VBG
hard-to-heal_JJ
wounds_NN
are_VPRT
driving_VBG
strong_JJ
We_FPP1
bring_VPRT
truly_RB
innovative_JJ
and_PHC
differentiating_JJ
growth_NN
in_PIN
the_DT
active_JJ
healing_GER
sector_NN
of_PIN
the_DT
technologies_NN
that_TSUB
meet_VPRT
the_DT
needs_NN
of_PIN
physicians_NN
,_,
advanced_VBD
wound_NN
management_NOMZ
market_NN
._.
We_FPP1
are_VPRT
marketing_VBG
our_FPP1
products_NN
ever_RB
more_EMPH
effectively_RB
We_FPP1
aim_VPRT
to_TO
raise_VB
operating_VBG
margins_NN
before_IN
through_PIN
expanded_VBN
and_PHC
specialised_VBN
global_JJ
goodwill_NN
amortisation_NOMZ
from_PIN
18_CD
%_NN
in_PIN
2002_CD
to_PIN
21_CD
%_NN
sales_NN
forces_NN
._.
in_PIN
2005_CD
,_,
moving_VBG [SUAV]
half_PDT
a_DT
percentage_NN
point_NN
closer_RB
to_PIN
that_DEMO
goal_NN
in_PIN
2003_CD
through_PIN
improvements_NOMZ
in_PIN
Our_FPP1
underlying_VBG
group_NN
sales_NN
increase_NN
was_VBD [BEMA]
14_CD
%_NN
in_PIN
operational_JJ
performance_NN
and_PHC
product_NN
mix_NN
._.
Sales_NN
in_PIN
North_NN
America_NN
grew_VBD
15_CD
%_NN
and_CC
the_DT
same_JJ
time_NN
we_FPP1
will_PRMD
continue_VB
to_TO
invest_VB
in_PIN
product_NN
region_NN
now_TIME
represents_VPRT
some_QUAN
56_CD
%_NN
of_PIN
the_DT
groups_NN
innovation_NOMZ
,_,
and_ANDC
in_PIN
growing_VBG
our_FPP1
sales_NN
teams_NN
by_PIN
business_NOMZ
._.
Sales_NN
growth_NN
in_PIN
Europe_NN
was_VBD [BEMA]
12_CD
%_NN
,_,
at_PIN
least_JJ
10_CD
%_NN
a_DT
year_NN
for_PIN
the_DT
foreseeable_JJ
future_NN
._.
reflecting_VBG [PRIV]
increased_VBN
healthcare_NN
spending_GER
and_CC
ageing_VBG
populations_NOMZ
._.
Sales_NN
in_PIN
the_DT
rest_NN
of_PIN
the_DT
world_NN
Orthopaedics_NN
grew_VBD
16_CD
%_NN
._.
Orthopaedics_NN
sales_NN
rose_VBD
by_PIN
an_DT
underlying_JJ
20_CD
%_NN
and_CC
its_PIT
performance_NN
continued_VBD
to_TO
outpace_VB
the_DT
market_NN
._.
Reconstructive_JJ
implant_VPRT
sales_NN
grew_VBD
by_PIN
an_DT
impressive_JJ
20_CD
%_NN
,_,
boosted_VBN [PASTP]
by_PIN
continued_JJ
04_CD
Smith_NN
&_CC
Nephew_NN
2002_CD
Oxinium_NN
knee_NN
implants_VPRT
ElectroBlade_NN
Resector_NN
His_TPP3
dream_NN
of_PIN
early_TIME
From_PIN
twenty_CD
years_NN
retirement_NOMZ
and_CC
new_JJ
life_NN
experience_NN
as_IN
an_DT
of_PIN
golf_NN
and_PHC
sailing_GER
went_VBD
aerobics_NN
instructor_NN
,_,
on_PIN
hold_NN
as_IN
osteoarthritis_NN
she_TPP3
understands_VPRT [PRIV]
the_DT
crippled_VBN
his_TPP3
plans_NN
._.
importance_NN
of_PIN
fitness_NOMZ
in_PIN
Frustrated_NN
by_PIN
increasing_VBG
a_DT
well-balanced_JJ
lifestyle_NN
._.
pain_NN
and_PHC
lack_NN
of_PIN
mobility_NOMZ
,_,
Thats_NN
why_RB
,_,
when_RB
she_TPP3
he_TPP3
consulted_VBD
his_TPP3
surgeon_NN
suffered_VBD
a_DT
torn_VBN
ligament_NOMZ
for_PIN
a_DT
solution_NOMZ
._.
Thanks_NN
in_PIN
her_TPP3
right_JJ
knee_NN
a_DT
year_NN
to_PIN
bilateral_JJ
Oxinium_NN
ago_RB
,_,
she_TPP3
wasted_VBD
no_SYNE
time_NN
knee_NN
implants_NN
,_,
this_DEMP
agreeing_VBG [SUAV] [PUBV]
to_PIN
her_TPP3
doctors_NN
retired_VBN
banker_NN
is_VPRT
back_RB
recommendation_NOMZ
for_PIN
on_PIN
course_NN
._.
Due_JJ
to_TO
reduced_VBN
pain_NN
and_PHC
recovery_NN
time_NN
,_,
she_TPP3
was_VBD [BEMA]
back_RB
at_PIN
the_DT
gym_NN
soon_TIME
after_IN
the_DT
procedure_NN
and_CC
enjoying_VBG
the_DT
benefits_NN
of_PIN
a_DT
healthy_JJ
lifestyle_NN
._.
Our_FPP1
operational_JJ
performance_NN
and_PHC
product_NN
mix_NN
is_VPRT [SPAU]
constantly_RB
being_VBG [PASS]
refined_VBN
to_TO
improve_VB
margins_NN
._.
surgeon_NN
response_NN
to_PIN
the_DT
additional_JJ
Oxinium_NN
will_PRMD
have_VB
responsibility_NOMZ
for_PIN
developing_VBG
global_JJ
knee_NN
products_NN
launched_VBN [WZPAST]
in_PIN
2002_CD
._.
We_FPP1
once_TIME
again_TIME
strategy_NN
and_CC
its_PIT
own_JJ
product_NN
development_NOMZ
,_,
recorded_VBN
industry-leading_JJ
growth_NN
in_PIN
this_DEMO
sector_NN
,_,
marketing_GER
and_PHC
sales_NN
functions_NOMZ
._.
They_TPP3
will_PRMD
share_VB
led_VBN
by_PIN
knee_NN
growth_NN
of_PIN
33_CD
%_NN
,_,
10_CD
%_NN
of_PIN
which_WDT [PIRE]
was_VBD [BEMA]
common_JJ
manufacturing_GER
and_PHC
support_NN
contributed_VBN [WZPAST]
by_PIN
the_DT
introduction_NOMZ
of_PIN
our_FPP1
joint_JJ
fluid_NN
organizations_NOMZ
._.
The_DT
sales_NN
forces_NN
in_PIN
major_JJ
therapy_NN
product_NN
,_,
Supartz_NN
._.
Hip_NN
sales_NN
grew_VBD
by_PIN
US_FPP1
cities_NOMZ
will_PRMD
be_VB [PASS]
specialised_VBN
into_PIN
separate_JJ
17_CD
%_NN
led_VBN [WZPAST]
by_PIN
continued_JJ
growth_NN
in_PIN
revision_NN
reconstructive_NN
and_PHC
trauma_NN
units_NN
on_PIN
a_DT
phased_VBN
procedures_NN
,_,
increased_VBD
penetration_NOMZ
of_PIN
our_FPP1
highly_AMP
basis_NN
beginning_GER
in_PIN
the_DT
first_JJ
quarter_NN
of_PIN
2003_CD
._.
cross_NN
linked_VBD
polyethylene_NN
liners_NN
and_CC
continued_VBD
strength_NN
in_PIN
our_FPP1
platform_NN
hip_NN
systems_NN
including_VBG [WZPRES]
Endoscopy_NN
Synergy_NN
and_PHC
Echelon_NN
._.
Endoscopy_JJ
sales_NN
grew_VBD
at_PIN
an_DT
underlying_VBG
10_CD
%_NN
Sales_NN
pricing_VBG [WZPRES]
in_PIN
Orthopaedics_NN
remained_VBD
positive_JJ
with_PIN
strong_JJ
growth_NN
coming_VBG [WZPRES]
from_PIN
outside_PLACE
the_DT
US_FPP1
._.
The_DT
company_NN
acquired_VBD
the_DT
ORATEC_NN
minimally_RB
invasive_JJ
joint_JJ
and_CC
spine_NN
business_NOMZ
in_PIN
the_DT
year_NN
,_,
The_DT
Oxinium_NN
knee_NN
has_VPRT [PEAS]
been_VBN [BEMA]
an_DT
outstanding_JJ
which_WDT
added_VBD [PUBV]
9_CD
%_NN
to_PIN
sales_NN
growth_NN
and_CC
has_VPRT [PEAS]
given_VBN
success_NN
since_OSUB
its_PIT
launch_NN
in_PIN
2001_CD
._.
We_FPP1
have_VPRT
us_FPP1
a_DT
leading_VBG
position_NOMZ
in_PIN
radio_NN
frequency_NN
continued_VBD
to_TO
invest_VB
in_PIN
the_DT
Oxinium_NN
program_NN
technology_NN
in_PIN
arthroscopy_JJ
._.
and_ANDC
Computer_NN
Assisted_NN
Surgery_NN
throughout_PIN
the_DT
year_NN
where_RB
we_FPP1
have_VPRT [PEAS]
received_VBN
US_FPP1
regulatory_JJ
Knee_NN
and_PHC
shoulder_NN
ligament_NOMZ
repair_NN
products_NN
approval_NN
for_PIN
hip_NN
,_,
knee_NN
and_PHC
trauma_NN
applications_NOMZ
._.
grew_VBD
particularly_RB
strongly_AMP
at_PIN
21_CD
%_NN
making_VBG [WZPRES]
the_DT
We_FPP1
have_VPRT [PEAS]
developed_VBN
an_DT
Oxinium_NN
femoral_JJ
head_NN
group_NN
the_DT
market_NN
leader_NN
in_PIN
arthroscopic_JJ
repair_NN
._.
for_PIN
hips_NN
and_CC
have_VPRT [SPAU] [PEAS]
already_RB
launched_VBN
the_DT
product_NN
New_NN
repair_NN
products_NN
were_VBD [PASS]
launched_VBN
during_PIN
the_DT
in_PIN
2003_CD
._.
year_NN
to_TO
strengthen_VB
our_FPP1
position_NOMZ
in_PIN
the_DT
arthroscopy_JJ
market_NN
,_,
including_VBG
TwinFix_NN
,_,
a_DT
specialised_JJ
shoulder_NN
We_FPP1
are_VPRT
creating_VBG
two_CD
divisions_NN
within_PIN
our_FPP1
repair_NN
device_NN
._.
New_NN
bioresorbable_JJ
screws_NN
for_PIN
orthopaedic_JJ
business_NOMZ
,_,
Reconstruction_NOMZ
and_PHC
ligament_NOMZ
fixation_NOMZ
performed_VBD
well_RB
._.
This_DEMO
initiative_NN
is_VPRT [PASS]
aimed_VBN
at_PIN
sustaining_VBG
has_VPRT [PEAS]
brought_VBN
us_FPP1
a_DT
unique_JJ
product_NN
that_TSUB
combines_VPRT
our_FPP1
industry_NN
leading_VBG [WZPRES]
performance_NN
by_PIN
improving_VBG
simultaneous_JJ
resection_NOMZ
with_PIN
coagulation_NOMZ
of_PIN
soft_JJ
the_DT
focus_NN
on_PIN
these_DEMO
separate_JJ
market_NN
sectors_NN
._.
We_FPP1
also_RB
introduced_VBD
a_DT
bipolar_NN
cutting_VBG [WZPRES]
This_DEMO
structure_NN
will_PRMD
enable_VB
us_FPP1
to_TO
bring_VB
technology_NN
and_PHC
ablation_NOMZ
system_NN
for_PIN
the_DT
Vulcan_NN
generator_NN
to_PIN
market_NN
faster_RB
and_CC
increase_VB
our_FPP1
customer_NN
responsiveness_NOMZ
and_PHC
satisfaction_NOMZ
._.
Each_QUAN
division_NN
Smith_NN
&_CC
Nephew_NN
2002_CD
05_CD
Business_NOMZ
overview_NN
Served_VBN
markets_NN
and_PHC
Business_NOMZ
growth_NN
in_PIN
2002_CD
overview_VBD
World_NN
market_NN
value_NN
Orthopaedics_NN
Growth_NN
:_:
13_CD
%_NN
A_DT
comprehensive_JJ
highly_AMP
advanced_JJ
range_NN
of_PIN
orthopaedic_JJ
implant_VB
and_PHC
trauma_VB
products_NN
._.
5.2_CD
bn_NN
Implants_NN
for_PIN
hips_NN
,_,
knees_NN
and_PHC
shoulders_NN
Trauma_NN
products_NN
for_PIN
severely_RB
broken_VBN
bones_NN
utilising_VBG [WZPRES]
internal_JJ
and_PHC
external_JJ
fixation_NOMZ
methods_NN
Clinical_JJ
therapies_NN
including_VBG [WZPRES]
ultrasound_NN
bone_NN
healing_VBG [WZPRES]
Market_NN
position_NOMZ
devices_NN
and_CC
joint_JJ
fluid_NN
therapy_NN
6th_JJ
We_FPP1
have_VPRT
a_DT
unique_JJ
range_NN
of_PIN
technology_NN
and_PHC
products_NN
which_WDT [WHSUB]
repair_VPRT
the_DT
human_JJ
body_NN
._.
We_FPP1
are_VPRT
World_NN
market_NN
value_NN
Endoscopy_NN
Growth_NN
:_:
6_CD
%_NN
Industry_NN
leader_NN
in_PIN
the_DT
development_NOMZ
and_PHC
commercialisation_NOMZ
of_PIN
endoscopic_JJ
minimally_RB
invasive_JJ
surgery_NN
products_NN
and_PHC
techniques_NN
._.
3.0_CD
bn_NN
Access_NN
Fluid_NN
management_NOMZ
and_PHC
insufflation_NOMZ
instruments_NOMZ
IDET_NN
procedure_NN
for_PIN
better_JJ
surgical_JJ
access_NN
._.
After_IN
years_NN
of_PIN
struggling_VBG
Visualisation_NOMZ
Digital_NN
cameras_NN
,_,
digital_JJ
image_NN
capture_NN
,_,
Market_NN
position_NOMZ
arthroscopy_NN
with_PIN
lower_JJ
back_RB
pain_NN
central_JJ
control_NN
,_,
multimedia_NN
broadcasting_VBG [WZPRES]
,_,
scopes_NN
,_,
resulting_VBG [PRESP]
from_PIN
a_DT
herniated_VBN
light_JJ
sources_NN
and_PHC
monitors_NN
to_TO
assist_VB
with_PIN
visualisation_NOMZ
._.
disc_NN
,_,
he_TPP3
was_VBD [BEMA]
able_PRED
to_TO
use_VB
Resection_NOMZ
State-of-the-art_JJ
radiofrequency_NN
wands_NN
,_,
1st_CD
his_TPP3
landscaping_GER
skills_NN
ElectroMechanical_NN
and_CC
mechanical_JJ
blades_NN
,_,
and_ANDC
hand_NN
once_TIME
again_TIME
after_IN
being_VBG
instruments_NOMZ
for_PIN
resecting_VBG
tissue_NN
._.
treated_VBN [PASTP]
with_PIN
Intradiscal_NN
Repair_NN
Specialised_NN
devices_NN
,_,
fixation_NOMZ
systems_NN
and_PHC
ElectroThermal_NN
Therapy_NN
bioabsorbable_JJ
materials_NN
to_TO
repair_VB
damaged_JJ
tissue_NN
._.
also_RB
known_VBN [PRIV]
as_IN
the_DT
IDET_NN
procedure_NN
._.
World_NN
market_NN
value_NN
Advanced_NN
Wound_NN
Management_NOMZ
Growth_NN
:_:
12_CD
%_NN
Advanced_NN
treatment_NOMZ
for_PIN
hard-to-heal_JJ
wounds_NN
offering_VBG [WZPRES]
a_DT
complete_JJ
range_NN
of_PIN
products_NN
from_PIN
initial_JJ
wound_NN
bed_NN
preparation_NOMZ
through_PIN
to_PIN
successful_JJ
wound_NN
closure_NN
._.
1.5_CD
bn_NN
These_DEMO
products_NN
are_VPRT [PASS]
targeted_VBN
particularly_RB
at_PIN
wounds_NN
connected_VBN [WZPAST]
with_PIN
the_DT
elderly_JJ
._.
Pressure_NN
ulcers_NN
Market_NN
position_NOMZ
Venous_NN
leg_NN
ulcers_NN
Diabetic_NN
foot_NN
ulcers_NN
Serious_JJ
burns_NN
1st_CD
For_PIN
more_EMPH
detailed_JJ
business_NOMZ
and_PHC
product_NN
information_NOMZ
visit_NN
:_:
www_NN
._.
com_NN
businesses_NOMZ
06_CD
Smith_NN
&_CC
Nephew_NN
2002_CD
What_WP
is_VPRT
driving_VBG
Our_FPP1
achievements_NOMZ
Our_FPP1
key_JJ
new_JJ
products_NN
market_NN
growth_NN
in_PIN
2002_CD
and_CC
developments_NOMZ
in_PIN
2002_CD
Ilizarov_NN
technique_NN
Both_DT
legs_NN
had_VBD [PEAS]
been_VBN [PASS]
deformed_VBN
since_OSUB
birth_NN
,_,
but_CC
on_PIN
September_NN
11_CD
,_,
2001_CD
,_,
she_TPP3
walked_VBD
down_RP
nearly_DWNT
Expanding_VBG
patient_JJ
pool_NN
Grew_VBD
sales_NN
20_CD
%_NN
Continued_VBN
rollout_NN
50_CD
flights_NN
of_PIN
World_NN
Trade_NN
Increasing_VBG [WZPRES]
numbers_NN
of_PIN
Expanded_JJ
global_JJ
sales_NN
of_PIN
Oxinium_NN
knee_NN
Center_NN
stairs_NN
to_PIN
safety_NN
._.
elderly_JJ
people_NN
living_VBG [WZPRES]
longer_RB
team_NN
by_PIN
12_CD
%_NN
applications_NOMZ
A_DT
surgeon_NN
had_VBD [PEAS]
corrected_VBN
Expectation_NOMZ
of_PIN
better_JJ
Over_IN
10,000_CD
Oxinium_NN
Accuris_NN
minimally_RB
invasive_JJ
her_TPP3
limbs_NN
using_VBG [WZPRES]
the_DT
Ilizarov_NN
quality_NOMZ
of_PIN
life_NN
knee_NN
implants_VPRT
uni-compartmental_JJ
knee_NN
technique_NN
._.
New_NN
,_,
longer-lasting_JJ
Over_IN
250_CD
Computer_NN
instrumentation_NOMZ
materials_NN
technology_NN
Assisted_VBN
total_JJ
knee_NN
Exogen_NN
3000_CD
Demand_NN
for_PIN
less_JJ
invasive_JJ
procedures_NN
newly_RB
OrthoGuard_NN
AB_NN
procedures_NN
branded_VBD
as_IN
Achieve_NN
antimicrobial_JJ
sleeve_NN
,_,
Patient_NN
knowledge_NN
due_JJ
Supartz_NN
joint_JJ
fluid_NN
the_DT
orthopaedic_NN
to_PIN
the_DT
internet_NN
and_PHC
media_NN
treatment_NOMZ
exceeding_VBG [WZPRES]
industrys_NN
first_RB
coated_JJ
medical_JJ
device_NN
Completed_VBN
new_JJ
to_TO
be_VB [BYPA]
cleared_VBN
by_PIN
the_DT
US_FPP1
manufacturing_GER
facility_NOMZ
regulatory_JJ
agency_NN
focusing_VBG [WZPRES]
on_PIN
three_CD
research_NN
areas_NN
non-invasive_JJ
stimulation_NOMZ
,_,
tissue_NN
engineering_GER
,_,
bioabsorbables_NN
._.
Increase_VB
in_PIN
sports_NN
injuries_NN
Grew_VBD
sales_NN
10_CD
%_NN
TwinFix_NN
bioabsorbable_JJ
More_EMPH
active_JJ
lifestyles_NN
Entry_NN
into_PIN
the_DT
minimally_RB
suture_JJ
anchor_VPRT
for_PIN
Increased_VBN
surgeon_NN
use_NN
invasive_JJ
spinal_JJ
market_NN
shoulder_NN
repair_NN
of_PIN
endoscopic_JJ
techniques_NN
through_PIN
ORATEC_NN
ElectroBlade_NN
Resector_NN
Innovative_JJ
technological_JJ
acquisition_NOMZ
Vulcan_NN
System_NN
RF_NN
developments_NOMZ
Launch_VPRT
of_PIN
the_DT
Digital_NN
generator_NN
Need_VBD
for_PIN
cost-effective_JJ
Operating_GER
Room_NN
concept_NN
Vision_NN
337_CD
Autoclavable_JJ
procedures_NN
in_PIN
hospitals_NN
Major_JJ
growth_NN
in_PIN
implants_NN
Camera_NN
System_NN
Growing_VBG [WZPRES]
demand_NN
for_PIN
for_PIN
soft_JJ
tissue_NN
repair_NN
Decompression_NN
Catheter_NN
digitally-integrated_VBD
Launched_VBN
industrys_NN
first_RB
for_PIN
herniated_VBN
discs_NN
OR_NN
equipment_NOMZ
ElectroMechanical_NN
Saphyre_NN
bipolar_NN
ablation_NOMZ
Growth_NN
in_PIN
ambulatory_JJ
resection_NOMZ
device_NN
probe_NN
ProGuide_NN
surgery_NN
centres_VPRT
Reached_VBN
30,000_CD
Having_VBG [PEAS]
developed_VBN
Payer_NN
support_NN
driven_VBN
procedures_NN
for_PIN
TriVex_NN
a_DT
venous_JJ
leg_NN
ulcer_NN
,_,
by_PIN
supporting_VBG
clinical_JJ
Launched_VBN
worldwide_NN
nurses_NN
at_PIN
his_TPP3
local_JJ
evidence_NN
network_NN
of_PIN
surgeon_NN
hospital_NN
agreed_VBD [SUAV] [PUBV]
to_TO
take_VB
training_GER
sites_NN
part_NN
in_PIN
the_DT
clinical_JJ
trial_NN
of_PIN
ProGuide_NN
,_,
a_DT
two-layer_JJ
elastic_JJ
compression_NN
More_EMPH
elderly_JJ
people_NN
Grew_VBD
sales_NN
11_CD
%_NN
Improved_VBN
and_PHC
extended_VBN
system_NN
designed_VBN [WZPAST]
for_PIN
living_VBG
longer_JJ
World_NN
leadership_NN
in_PIN
Allevyn_NN
range_NN
launched_VBD
venous_JJ
leg_NN
ulcers_NN
._.
This_DEMO
More_EMPH
clinically_RB
advanced_VBN
advanced_JJ
wound_NN
care_NN
Continued_VBN
global_JJ
roll-out_PIN
allowed_VBD [SUAV]
the_DT
correct_JJ
methods_NN
of_PIN
healing_VBG
wounds_NN
strengthened_VBD
of_PIN
Acticoat_NN
silver_NN
burns_NN
pressure_NN
to_TO
be_VB [PASS]
applied_VBN
Therapies_NN
that_TSUB
reduce_VPRT
Allevyn_NN
,_,
our_FPP1
largest_JJ
dressing_VBG
and_PHC
reduced_VBD
the_DT
number_NN
nursing_GER
time_NN
and_PHC
speed_NN
product_NN
,_,
grew_VBD
21_CD
%_NN
Global_JJ
launch_NN
of_PIN
Cutinova_NN
of_PIN
dressing_VBG
changes_NN
._.
recovery_NN
for_PIN
cost_NN
efficiency_NN
Acticoat_NN
burns_NN
dressing_VBG [WZPRES]
Hydro_NN
and_PHC
range_NN
Two-thirds_NN
of_PIN
global_JJ
market_NN
increased_VBD
sales_NN
by_PIN
65_CD
%_NN
extension_NN
still_RB
to_TO
be_VB [PASS]
converted_VBN
to_PIN
Successful_JJ
launch_NN
of_PIN
Dermagraft_NN
full_JJ
US_FPP1
launch_NN
advanced_VBD
wound_NN
healing_VBG [WZPRES]
Wound_JJ
Bed_NN
Preparation_NOMZ
New_NN
,_,
advanced_VBD
concept_NN
technologies_NN
expanding_VBG [WZPRES]
100_CD
%_NN
ownership_NN
of_PIN
breadth_NN
of_PIN
market_NN
Dermagraft_NN
and_PHC
TransCyte_NN
88_CD
%_NN
coverage_NN
of_PIN
US_FPP1
outpatient_NN
population_NOMZ
for_PIN
Dermagraft_NN
on_PIN
an_DT
underlying_JJ
basis_NN
Smith_NN
&_CC
Nephew_NN
2002_CD
07_CD
Acticoat_NN
Oxinium_NN
hip_NN
implant_VPRT
She_TPP3
tried_VBD
to_TO
help_VB
her_TPP3
Although_CONC
he_TPP3
could_POMD
have_VB
mother_NN
with_PIN
the_DT
cooking_GER
delayed_VBD
his_TPP3
total_JJ
hip_NN
but_CC
she_TPP3
pulled_VBD
a_DT
pan_VB
of_PIN
replacement_NOMZ
surgery_NN
boiling_VBG [WZPRES]
water_NN
off_PIN
the_DT
until_IN
after_IN
his_TPP3
daughters_NN
stove_VPRT
,_,
causing_VBG
mixed_JJ
wedding_GER
,_,
Smith_NN
&_CC
partial_JJ
thickness_NOMZ
burns_NN
Nephews_NN
mini-incision_NN
to_PIN
her_TPP3
arms_NN
and_CC
upper_JJ
technique_NN
,_,
in_PIN
concert_NN
torso_NN
._.
In_PIN
the_DT
burns_NN
unit_NN
with_PIN
an_DT
Oxinium_NN
implant_VPRT
,_,
at_PIN
the_DT
hospital_NN
,_,
Acticoat_NN
,_,
restored_VBD
his_TPP3
pain-free_NN
a_DT
unique_JJ
antimicrobial_JJ
mobility_NOMZ
in_PIN
time_NN
to_TO
give_VB
barrier_NN
dressing_VBG [WZPRES]
,_,
was_VBD [BEMA]
away_PLACE
the_DT
bride_NN
and_CC
take_VB
applied_VBN
to_PIN
the_DT
affected_VBN
a_DT
full_JJ
part_NN
in_PIN
this_DEMO
important_JJ
areas_NN
,_,
helping_VBG
to_TO
minimize_VB
day_NN
in_PIN
his_TPP3
daughters_NN
life_NN
._.
the_DT
risk_NN
of_PIN
infection_NOMZ
and_PHC
scarring_GER
._.
The_DT
burns_NN
healed_VBD
quickly_RB
,_,
allowing_VBG [SUAV] [PRESP]
her_TPP3
to_TO
rejoin_VB
her_TPP3
playmates_NN
at_PIN
nursery_NN
school_NN
._.
Our_FPP1
commercially_RB
orientated_VBN
innovation_NOMZ
is_VPRT
contributing_VBG
a_DT
strong_JJ
new_JJ
product_NN
pipeline_NN
,_,
Sustaining_VBG [PRESP]
our_FPP1
growth_NN
rate_NN
Chief_NN
Executives_NN
Over_IN
the_DT
past_JJ
few_QUAN
years_NN
we_FPP1
have_VPRT [PEAS]
maintained_VBN [PUBV]
consistently_RB
strong_JJ
investment_NOMZ
in_PIN
expanding_VBG
the_DT
statement_NOMZ
continued_VBD
sales_NN
force_NN
and_CC
expanding_VBG
our_FPP1
product_NN
pipeline_NN
._.
In_PIN
2002_CD
we_FPP1
expanded_VBD
the_DT
Orthopaedics_NN
sales_NN
and_CC
a_DT
thermal_JJ
decompression_NN
catheter_NN
for_PIN
team_NN
by_PIN
12_CD
%_NN
,_,
the_DT
Endoscopy_NN
team_NN
by_PIN
30_CD
%_NN
herniated_VBD
spinal_JJ
discs_NN
._.
The_DT
Digital_NN
Operating_GER
including_VBG [WZPRES]
the_DT
sales_NN
force_NN
acquired_VBN [WZPAST]
with_PIN
ORATEC_NN
,_,
Room_NN
concept_NN
gained_VBD
ground_NN
with_PIN
installations_NOMZ
and_CC
the_DT
Advanced_NN
Wound_NN
Management_NOMZ
team_NN
in_PIN
leading_VBG
hospitals_NN
._.
1_CD
Advanced_NN
Wound_NN
Management_NOMZ
We_FPP1
invested_VBD
5_CD
2_CD
%_NN
of_PIN
sales_NN
revenue_NN
in_PIN
research_NN
In_PIN
its_PIT
first_JJ
full_JJ
year_NN
as_IN
an_DT
advanced_JJ
wound_NN
and_PHC
development_NOMZ
across_PLACE
our_FPP1
businesses_NOMZ
._.
In_PIN
management_NOMZ
business_NOMZ
,_,
we_FPP1
strengthened_VBD
our_FPP1
2002_CD
,_,
products_NN
introduced_VBN [WZPAST]
in_PIN
the_DT
last_JJ
three_CD
years_NN
world-leading_JJ
position_NOMZ
in_PIN
advanced_JJ
treatments_NOMZ
rose_VBD
to_PIN
18_CD
%_NN
of_PIN
sales_NN
._.
Our_FPP1
group_NN
focus_NN
on_PIN
unique_JJ
for_PIN
hard-to-heal_JJ
wounds_NN
._.
Underlying_JJ
sales_NN
methods_NN
to_TO
repair_VB
and_PHC
heal_VB
the_DT
human_JJ
body_NN
growth_NN
was_VBD [BEMA]
11_CD
%_NN
,_,
with_PIN
the_DT
Allevyn_NN
product_NN
range_NN
has_VPRT [PEAS]
led_VBN
to_PIN
group_NN
wide_JJ
research_NN
in_PIN
three_CD
fields_NN
:_:
achieving_VBG [PRESP]
21_CD
%_NN
._.
We_FPP1
have_VPRT [SPAU] [PEAS]
successfully_RB
integrated_VBN
bioresorbable_JJ
materials_NN
to_TO
facilitate_VB
healing_GER
and_CC
into_PIN
the_DT
business_NOMZ
the_DT
advanced_JJ
wound_NN
products_NN
surgical_JJ
reconstruction_NOMZ
:_:
tissue_NN
engineering_GER
to_PIN
of_PIN
Beiersdorf_NN
and_CC
the_DT
Acticoat_NN
silver_NN
product_NN
for_PIN
help_NN
replace_VB
,_,
repair_VB
and_PHC
regenerate_VB
damaged_JJ
burns_NN
acquired_VBN [WZPAST]
in_PIN
2001_CD
and_CC
these_DEMO
products_NN
are_VPRT
tissue_NN
:_:
and_ANDC
non-invasive_JJ
devices_NN
to_TO
stimulate_VB
growing_VBG
strongly_AMP
._.
Towards_PIN
the_DT
end_NN
of_PIN
the_DT
year_NN
,_,
we_FPP1
secured_VBD
100_CD
%_NN
Enhancing_VBG [WZPRES]
manufacturing_GER
capacity_NOMZ
and_PHC
quality_NOMZ
ownership_NN
of_PIN
the_DT
Dermagraft_NN
and_PHC
TransCyte_NN
To_TO
meet_VB
future_JJ
sales_NN
growth_NN
we_FPP1
expanded_VBD
our_FPP1
arrangement_NOMZ
by_PIN
acquiring_VBG
ATSs_NN
50_CD
%_NN
share_NN
._.
Orthopaedics_NN
and_CC
Endoscopy_JJ
manufacturing_GER
Reimbursement_NOMZ
for_PIN
Dermagraft_NN
continues_VPRT
to_PIN
capacity_NOMZ
._.
Orthopaedics_NN
enlarged_JJ
its_PIT
production_NOMZ
progress_NN
well_RB
,_,
with_PIN
88_CD
%_NN
of_PIN
the_DT
outpatient_NN
space_NN
in_PIN
Memphis_NN
,_,
Tennessee_NN
,_,
by_PIN
about_IN
a_DT
third_JJ
._.
population_NOMZ
now_TIME
covered_VBN
in_PIN
the_DT
US_FPP1
._.
Sales_NN
of_PIN
Endoscopy_NN
expanded_VBD
two_CD
factories_NN
and_CC
moved_VBD [SUAV]
Dermagraft_NN
in_PIN
its_PIT
US_FPP1
launch_NN
year_NN
achieved_VBD
3m_CD
._.
its_PIT
headquarters_NN
to_PIN
new_JJ
premises_NN
near_PLACE
its_PIT
production_NOMZ
facility_NOMZ
in_PIN
Andover_NN
,_,
Massachusetts_NN
._.
Advanced_NN
Wound_NN
Management_NOMZ
has_VPRT [PEAS]
begun_VBN
08_CD
Smith_NN
&_CC
Nephew_NN
2002_CD
Allevyn_NN
TwinFix_NN
bioabsorbable_JJ
Following_VBG
a_DT
long_JJ
illness_NOMZ
,_,
suture_NN
anchor_VB
she_TPP3
suffered_VBD
from_PIN
a_DT
He_TPP3
was_VBD [BEMA]
a_DT
talented_JJ
tennis_NN
severe_JJ
pressure_NN
ulcer_NN
player_NN
in_PIN
college_NN
,_,
and_ANDC
he_TPP3
around_PLACE
the_DT
sacral_JJ
area_NN
,_,
never_RB
lost_VBD
his_TPP3
love_NN
for_PIN
the_DT
causing_VBG
much_QUAN
pain_NN
and_PHC
sport_NN
._.
After_IN
suffering_VBG
a_DT
discomfort_NN
,_,
and_ANDC
limiting_VBG
serious_JJ
rotator_NN
cuff_NN
injury_NN
,_,
her_TPP3
mobility_NOMZ
._.
Despite_PIN
the_DT
his_TPP3
days_NN
of_PIN
swinging_VBG
a_DT
efforts_NN
of_PIN
a_DT
district_NN
nurse_NN
,_,
racket_NN
seemed_VBD [SMP]
to_TO
have_VB
it_PIT
wasnt_VB
until_IN
Allevyn_NN
vanished_VBD
forever_RB
._.
But_CC
Sacral_NN
was_VBD [PASS]
used_VBN
,_,
a_DT
thanks_NN
to_PIN
the_DT
use_NN
of_PIN
shaped_JJ
,_,
highly_AMP
absorbent_JJ
a_DT
TwinFix_NN
bioabsorbable_JJ
hydrocellular_JJ
dressing_VBG
,_,
suture_NN
anchor_VB
by_PIN
his_TPP3
that_DEMO
the_DT
ulcer_NN
showed_VBD [PRIV]
surgeon_NN
,_,
he_TPP3
is_VPRT [BEMA]
back_RB
on_PIN
any_QUAN
signs_NN
of_PIN
improvement_NOMZ
._.
the_DT
court_NN
twice_RB
a_DT
week_NN
After_IN
a_DT
few_QUAN
weeks_NN
the_DT
and_CC
easing_VBG
the_DT
stress_NN
of_PIN
pain_NN
was_VBD [PASS]
alleviated_VBN
,_,
the_DT
work_NN
with_PIN
some_QUAN
friendly_JJ
pressure_NN
ulcer_NN
healed_VBD
and_CC
competition_NOMZ
from_PIN
the_DT
mobility_NOMZ
was_VBD [PASS]
restored_VBN
._.
and_ANDC
surgeon_NN
medical_JJ
education_NOMZ
programs_NN
are_VPRT
continuing_VBG
to_TO
speed_VB
product_NN
adoption_NOMZ
._.
building_VBG [PRESP]
a_DT
new_JJ
manufacturing_GER
plant_NN
in_PIN
Largo_NN
,_,
Our_FPP1
complete_JJ
Sustainability_NOMZ
Report_NN
is_VPRT [PASS]
published_VBN
Florida_NN
,_,
near_PLACE
its_PIT
existing_VBG
facilities_NOMZ
._.
We_FPP1
continue_VPRT
to_TO
maintain_VB [PUBV]
rigorous_JJ
quality_NOMZ
Outlook_NN
assurance_NN
and_PHC
control_NN
systems_NN
that_TSUB
are_VPRT [BEMA]
subject_PRED
We_FPP1
are_VPRT [BEMA]
in_PIN
the_DT
next_JJ
phase_NN
of_PIN
our_FPP1
companys_NN
to_PIN
regular_JJ
internal_JJ
and_PHC
external_JJ
review_NN
._.
We_FPP1
have_VPRT [PEAS]
focused_VBN
our_FPP1
businesses_NOMZ
product_NN
quality_NOMZ
very_AMP
seriously_RB
and_CC
are_VPRT [PASS]
committed_VBN
on_PIN
three_CD
high-growth_NN
medical_JJ
device_NN
sectors_NN
._.
to_PIN
the_DT
highest_JJ
standards_NN
of_PIN
manufacturing_VBG
quality_NOMZ
._.
We_FPP1
are_VPRT
delivering_VBG
sustained_VBN
growth_NN
in_PIN
sales_NN
and_CC
underlying_VBG
operating_VBG
margins_NN
._.
Business_NOMZ
Development_NOMZ
In_PIN
March_NN
we_FPP1
completed_VBD
our_FPP1
restructuring_GER
with_PIN
We_FPP1
have_VPRT
excellent_JJ
management_NOMZ
teams_NN
in_PIN
place_NN
,_,
the_DT
disposal_NN
of_PIN
our_FPP1
Rehabilitation_NOMZ
business_NOMZ
to_PIN
intent_NN
on_PIN
building_GER
sales_NN
and_PHC
market_NN
share_NN
as_RB
well_RB
AbilityOne_NN
in_PIN
the_DT
US_FPP1
._.
We_FPP1
received_VBD
71m_CD
in_PIN
cash_NN
as_IN
improving_VBG
the_DT
financial_JJ
performance_NN
of_PIN
their_TPP3
and_CC
retained_VBD
a_DT
21.5_CD
%_NN
interest_NN
in_PIN
the_DT
enlarged_JJ
businesses_NOMZ
._.
Our_FPP1
new_JJ
products_NN
are_VPRT
advancing_VBG
company_NN
to_TO
benefit_VB
from_PIN
the_DT
substantial_JJ
value_NN
clinical_JJ
performance_NN
by_PIN
benefiting_VBG
both_DT
patients_NN
that_TOBJ
we_FPP1
believe_VPRT [PRIV]
will_PRMD
be_VB [BYPA]
created_VBN
by_PIN
combining_VBG
and_CC
healthcare_NN
systems_NN
._.
Our_FPP1
sales_NN
people_NN
the_DT
two_CD
businesses_NOMZ
._.
continue_VB
to_TO
be_VB [BYPA]
excited_VBN
by_PIN
our_FPP1
product_NN
ranges_NN
and_CC
we_FPP1
have_VPRT
every_QUAN
reason_NN
to_TO
expect_VB [PRIV]
that_THVC
our_FPP1
Our_FPP1
joint_JJ
venture_NN
with_PIN
Beiersdorf_NN
,_,
BSN_NN
Medical_NN
,_,
markets_NN
will_PRMD
themselves_TPP3
continue_VB
to_TO
grow_VB
._.
We_FPP1
had_VBD
a_DT
successful_JJ
trading_GER
year_NN
._.
BSN_NN
and_CC
remain_VPRT
confident_JJ
that_THAC
we_FPP1
can_POMD
deliver_VB
sustainable_JJ
AbilityOne_NN
made_VBD
a_DT
combined_VBN
operating_GER
profit_NN
growth_NN
over_IN
the_DT
next_JJ
three_CD
years_NN
._.
Corporate_JJ
social_JJ
responsibility_NOMZ
We_FPP1
are_VPRT [PASS]
committed_VBN
to_PIN
sustainable_JJ
development_NOMZ
,_,
reducing_VBG [PRESP]
our_FPP1
impact_NN
on_PIN
the_DT
environment_NOMZ
while_OSUB
contributing_VBG
to_PIN
the_DT
quality_NOMZ
of_PIN
life_NN
enjoyed_VBN [WZPAST]
by_PIN
society_NN
at_PIN
large_JJ
._.
We_FPP1
support_VPRT
local_JJ
communities_NOMZ
Christopher_NN
ODonnell_NN
around_PLACE
our_FPP1
manufacturing_GER
operations_NOMZ
and_CC
play_VB
Chief_NN
Executive_NN
a_DT
substantial_JJ
role_NN
in_PIN
professional_JJ
education_NOMZ
in_PIN
our_FPP1
clinical_JJ
fields_NN
._.
Smith_NN
&_CC
Nephew_NN
2002_CD
09_CD
The_DT
Board_NN
Non-executive_JJ
directors_NN
Dudley_NN
Eustace_NN
66_CD
Christopher_NN
Peter_NN
Hooley_NN
56_CD
Dr_NN
Pamela_NN
Kirby_NN
49_CD
Members_NN
of_PIN
the_DT
Chairman_NN
ODonnell_NN
56_CD
Finance_NN
Director_NN
Appointed_VBD
a_DT
director_NN
Remuneration_NOMZ
Appointed_VBD
Deputy_NN
Chief_NN
Executive_NN
He_TPP3
joined_VBD
the_DT
group_NN
in_PIN
March_NN
2002_CD
._.
Committee_NN
Chairman_NN
in_PIN
1999_CD
and_CC
He_TPP3
joined_VBD
the_DT
group_NN
and_CC
was_VBD [PASS]
appointed_VBN
She_TPP3
is_VPRT
Chief_NN
Executive_NN
Members_NN
of_PIN
the_DT
Chairman_NN
in_PIN
January_NN
in_PIN
1988_CD
and_CC
was_VBD [BEMA]
a_DT
director_NN
in_PIN
1991_CD
._.
Officer_NN
of_PIN
Quintiles_NN
Audit_NN
Committee_NN
2000_CD
._.
He_TPP3
is_VPRT [PASS]
Chairman_NN
appointed_VBN
a_DT
director_NN
He_TPP3
is_VPRT [BEMA]
a_DT
non-executive_JJ
Transnational_JJ
Members_NN
of_PIN
the_DT
of_PIN
the_DT
Nominations_NOMZ
in_PIN
1992_CD
._.
He_TPP3
was_VBD
director_NN
of_PIN
Cobham_NN
plc._NN
._.
Nominations_NOMZ
Committee_NN
,_,
nonappointed_JJ
Chief_NN
Committee_NN
executive_NN
Chairman_NN
Executive_NN
in_PIN
1997_CD
._.
of_PIN
Sendo_NN
Holdings_GER
plc_NN
He_TPP3
is_VPRT [BEMA]
a_DT
non-executive_JJ
Kenneth_NN
Kemp_NN
is_VPRT
and_CC
a_DT
non-executive_JJ
director_NN
of_PIN
BOC_NN
Group_NN
._.
director_NN
of_PIN
KLM_NN
Royal_NN
Dutch_NN
Airlines_NN
NV_NN
,_,
Aegon_NN
NV_NN
,_,
Hagemeyer_NN
NV_NN
,_,
Royal_NN
KPN_NN
NV_NN
and_PHC
Sonae_NN
._.
We_FPP1
feel_VPRT [PRIV]
that_THVC
our_FPP1
innovative_JJ
and_PHC
responsive_JJ
company_NN
is_VPRT [BEMA]
in_PIN
a_DT
good_JJ
position_NOMZ
for_PIN
future_JJ
growth_NN
,_,
Dr_NN
Alan_NN
Suggett_NN
59_CD
Group_NN
Director_NN
of_PIN
Group_NN
Technology_NN
He_TPP3
joined_VBD
the_DT
group_NN
in_PIN
1982_CD
and_CC
was_VBD [PASS]
Executive_NN
appointed_VBN [WZPAST]
to_PIN
the_DT
Group_NN
Executive_NN
Committee_NN
in_PIN
Committee_NN
1986_CD
._.
David_NN
Illingworth_NN
49_CD
President_NN
Orthopaedics_NN
Christopher_NN
ODonnell_NN
,_,
He_TPP3
joined_VBD
the_DT
group_NN
and_PHC
Chief_NN
Executive_NN
was_VBD [PASS]
appointed_VBN
to_PIN
the_DT
Group_NN
See_VB [PRIV]
above_PLACE
._.
Peter_NN
Hooley_NN
,_,
Finance_NN
Director_NN
See_VB [PRIV]
above_PLACE
._.
Peter_NN
Huntley_NN
42_CD
Jim_NN
Taylor_NN
46_CD
Group_NN
Director_NN
Strategy_NN
Group_NN
Director_NN
Indirect_NN
and_PHC
Business_NOMZ
Development_NOMZ
Markets_NN
He_TPP3
joined_VBD
the_DT
He_TPP3
joined_VBD
the_DT
group_NN
and_PHC
group_NN
and_CC
was_VBD [PASS]
appointed_VBN
was_VBD [PASS]
appointed_VBN
to_PIN
the_DT
Group_NN
to_PIN
the_DT
Group_NN
Executive_NN
Executive_NN
Committee_NN
Committee_NN
in_PIN
2000_CD
._.
in_PIN
1998_CD
._.
10_CD
Smith_NN
&_CC
Nephew_NN
2002_CD
Warren_NN
Knowlton_NN
56_CD
Brian_NN
Larcombe_NN
49_CD
Richard_NN
fide_NN
Schutter_NN
Dr_NN
Rolf_NN
Stomberg_NN
62_CD
Sir_NN
Timothy_NN
Lankester_NN
Appointed_VBD
a_DT
director_NN
Appointed_VBN
a_DT
director_NN
62_CD
Appointed_VBN
a_DT
A_DT
director_NN
since_OSUB
1998_CD
._.
60_CD
A_DT
director_NN
since_OSUB
in_PIN
November_NN
2000_CD
._.
in_PIN
March_NN
2002_CD
._.
He_TPP3
director_NN
in_PIN
January_NN
Senior_JJ
independent_JJ
June_NN
1996_CD
._.
He_TPP3
is_VPRT [BEMA]
He_TPP3
is_VPRT
Chairman_NN
of_PIN
the_DT
is_VPRT
Chief_NN
Executive_NN
of_PIN
2001_CD
._.
He_TPP3
is_VPRT [BEMA]
a_DT
nondirector_NN
and_PHC
Chairman_NN
president_NN
of_PIN
Corpus_NN
Audit_NN
Committee_NN
and_PHC
3i_NN
Group_NN
Plc._NN
._.
executive_JJ
director_NN
of_PIN
the_DT
Remuneration_NOMZ
Christi_NN
College_NN
,_,
Oxford_NN
._.
Group_NN
Chief_NN
Executive_NN
of_PIN
Varian_NN
Inc._NN
._.
ING_NN
Committee_NN
._.
He_TPP3
is_VPRT [BEMA]
Also_RB
an_DT
independent_JJ
of_PIN
Morgan_NN
Crucible_NN
plc._NN
._.
Americas_NN
,_,
Incyte_NN
Chairman_NN
of_PIN
director_NN
of_PIN
the_DT
London_NN
Genomics_NN
,_,
MedPointe_NN
Management_NOMZ
Metal_NN
Exchange_NN
and_PHC
Pharmaceuticals_NN
and_PHC
Consulting_GER
Group_NN
PLC_NN
Deputy_NN
Chairman_NN
of_PIN
General_NN
Binding_GER
and_CC
a_DT
non-executive_JJ
the_DT
British_JJ
Council_NN
._.
director_NN
of_PIN
Scania_NN
AB_NN
,_,
Stinnes_NN
AG_NN
,_,
Reed_NN
Elsevier_NN
plc_NN
,_,
Cordiant_NN
Communications_NOMZ
plc_NN
,_,
Deutsche_NN
BP_NN
AG_NN
,_,
TPG_NN
Group_NN
and_PHC
Hoyer_NN
GmbH_NN
._.
with_PIN
7,500_CD
employees_NN
who_WP [WHSUB]
commit_VPRT
their_TPP3
energy_NN
and_PHC
expertise_NN
to_PIN
its_PIT
continual_JJ
improvement_NOMZ
._.
Paul_NN
Williams_NN
56_CD
Jim_NN
Ralston_NN
56_CD
Group_NN
Director_NN
Human_NN
Chief_NN
Legal_NN
Officer_NN
Resources_NN
He_TPP3
joined_VBD
the_DT
He_TPP3
joined_VBD
the_DT
group_NN
in_PIN
1999_CD
group_NN
and_CC
was_VBD [PASS]
appointed_VBN
and_PHC
was_VBD [PASS]
appointed_VBN
to_PIN
the_DT
to_PIN
the_DT
Group_NN
Executive_NN
Group_NN
Executive_NN
Committee_NN
Committee_NN
in_PIN
1998_CD
._.
in_PIN
2002_CD
._.
Jim_NN
Dick_NN
50_CD
Ron_NN
Sparks_VPRT
47_CD
President_NN
Wound_NN
President_NN
Endoscopy_NN
Management_NOMZ
He_TPP3
joined_VBD
He_TPP3
joined_VBD
the_DT
group_NN
in_PIN
the_DT
group_NN
in_PIN
1977_CD
and_CC
was_VBD [BEMA]
1983_CD
and_CC
was_VBD [PASS]
appointed_VBN
appointed_VBN
to_PIN
the_DT
Group_NN
to_PIN
the_DT
Group_NN
Executive_NN
Executive_NN
Committee_NN
Committee_NN
in_PIN
1999_CD
._.
in_PIN
1999_CD
._.
Smith_NN
&_CC
Nephew_NN
2002_CD
11_CD
Corporate_JJ
social_JJ
responsibility_NOMZ
We_FPP1
aim_VPRT
to_TO
make_VB
our_FPP1
values_NN
of_PIN
Performance_NN
,_,
Innovation_NOMZ
More_EMPH
detail_NN
on_PIN
our_FPP1
policies_NN
and_CC
the_DT
work_NN
which_WDT [WHOBJ]
we_FPP1
and_CC
Trust_NN
integral_JJ
to_PIN
the_DT
way_NN
we_FPP1
operate_VPRT
,_,
and_ANDC
are_VPRT
do_VB [PROD]
in_PIN
these_DEMO
areas_NN
is_VPRT [PASS]
provided_VBN
in_PIN
the_DT
following_VBG
text_NN
._.
committed_VBN [PASTP]
to_PIN
the_DT
principles_NN
of_PIN
sustainable_JJ
development_NOMZ
._.
This_DEMP
was_VBD [BYPA]
recognized_VBN [PRIV]
by_PIN
our_FPP1
admission_NN
in_PIN
2002_CD
on_PIN
our_FPP1
Environmental_JJ
management_NOMZ
first_RB
application_NOMZ
to_PIN
the_DT
Dow_NN
Jones_NN
Sustainability_NOMZ
Index_NN
._.
We_FPP1
are_VPRT [PASS]
committed_VBN
to_TO
continuing_VBG
reduction_NOMZ
in_PIN
our_FPP1
This_DEMP
is_VPRT [BEMA]
the_DT
most_EMPH
widely_RB
recognized_VBN [PRIV]
arbiter_NN
of_PIN
good_JJ
practice_NN
environmental_JJ
impact_NN
:_:
we_FPP1
use_VPRT
renewable_JJ
resources_NN
and_CC
we_FPP1
achieved_VBD
the_DT
highest_JJ
rating_NN
in_PIN
our_FPP1
business_NOMZ
sector_NN
._.
wherever_RB
possible_JJ
and_CC
reduce_VB
any_QUAN
adverse_JJ
effect_NN
from_PIN
products_NN
and_CC
processes_VPRT
to_PIN
a_DT
practical_JJ
minimum_NN
._.
Our_FPP1
We_FPP1
published_VBD
our_FPP1
second_JJ
Sustainability_NOMZ
Report_NN
in_PIN
April_NN
business_NOMZ
units_NN
must_NEMD
take_VB
effective_JJ
action_NOMZ
to_TO
control_VB
risks_NN
2002_CD
,_,
outlining_VBG [PRESP]
our_FPP1
progress_NN
in_PIN
corporate_JJ
social_JJ
responsibility_NOMZ
and_CC
minimize_VB
environmental_JJ
impacts_NN
through_PIN
systems_NN
CSR_NN
._.
It_PIT
was_VBD [BEMA]
more_EMPH
detailed_PRED
and_PHC
wider_PRED
in_PIN
scope_NN
than_PIN
the_DT
and_CC
procedures_NN
based_VBN [WZPAST]
on_PIN
a_DT
thorough_JJ
understanding_GER
first_RB
,_,
with_PIN
increased_VBN
measurement_NOMZ
data_NN
and_PHC
information_NOMZ
of_PIN
the_DT
risks_NN
and_PHC
provision_NN
of_PIN
appropriate_JJ
training_GER
and_CC
on_PIN
our_FPP1
activities_NOMZ
._.
Progress_NN
is_VPRT [PASS]
reviewed_VBN
annually_RB
by_PIN
the_DT
Board_NN
._.
The_DT
third_JJ
Sustainability_NOMZ
Report_NN
will_PRMD
be_VB [PASS]
published_VBN
on_PIN
our_FPP1
Over_IN
the_DT
past_JJ
10_CD
years_NN
our_FPP1
environmental_JJ
management_NOMZ
website_NN
in_PIN
April_NN
and_CC
will_PRMD
include_VB
new_JJ
measurement_NOMZ
systems_NN
have_VPRT [PEAS]
delivered_VBN
cost_NN
savings_GER
as_RB
well_RB
as_IN
initiatives_NN
,_,
especially_RB
in_PIN
the_DT
social_JJ
area_NN
._.
At_PIN
the_DT
same_JJ
time_NN
environmental_JJ
benefits_NN
._.
Our_FPP1
manufacturing_GER
processes_VPRT
we_FPP1
will_PRMD
be_VB
publishing_VBG
a_DT
new_JJ
Code_NN
of_PIN
Business_NOMZ
Principles_NN
are_VPRT [BEMA]
relatively_RB
low_PRED
in_PIN
environmental_JJ
impact_NN
with_PIN
locations_NOMZ
in_PIN
which_WDT [PIRE]
brings_VPRT
together_RB
policies_NN
that_TSUB
currently_RB
appear_VPRT [SMP]
in_PIN
the_DT
US_FPP1
,_,
UK_NN
and_PHC
Germany_NN
._.
Our_FPP1
main_JJ
environmental_JJ
impact_NN
different_JJ
sections_NOMZ
of_PIN
our_FPP1
website_NN
,_,
updated_VBN
and_PHC
broadened_VBN
comes_VPRT
from_PIN
waste_NN
generated_VBD
at_PIN
manufacturing_VBG
sites_NN
._.
We_FPP1
have_VPRT [PEAS]
included_VBN
purchasing_VBG
policies_NN
with_PIN
We_FPP1
operate_VPRT
waste_NN
prevention_NOMZ
and_PHC
minimisation_NOMZ
programs_NN
particular_JJ
emphasis_NN
on_PIN
human_JJ
rights_NN
and_PHC
suppliers_NN
throughout_PIN
the_DT
group_NN
and_CC
are_VPRT
examining_VBG
ways_NN
of_PIN
assessing_VBG
practices_NN
on_PIN
health_NN
,_,
safety_NN
and_CC
environmental_JJ
standards_NN
._.
sustainable_JJ
development_NOMZ
aspects_NN
of_PIN
our_FPP1
products_NN
._.
In_PIN
the_DT
Through_PIN
this_DEMO
code_NN
we_FPP1
ensure_VPRT [SUAV] [PRIV]
that_THVC
our_FPP1
planning_GER
and_CC
past_JJ
year_NN
we_FPP1
have_VPRT [PEAS]
focused_VBN
on_PIN
reducing_VBG
waste_NN
,_,
the_DT
business_NOMZ
decisions_NN
take_VPRT
account_NN
of_PIN
ethical_JJ
,_,
social_JJ
,_,
legal_JJ
improvement_NOMZ
in_PIN
recycling_VBG
made_VBN
in_PIN
2001_CD
has_VPRT [PEAS]
been_VBN [PASS]
sustained_VBN
and_CC
financial_JJ
considerations_NOMZ
,_,
thereby_RB
minimizing_VBG
risks_NN
and_PHC
emissions_NN
are_VPRT [BEMA]
down_RB
12_CD
%_NN
._.
This_DEMP
is_VPRT [BEMA]
a_DT
significant_JJ
and_CC
balancing_VBG
the_DT
interests_NN
of_PIN
all_QUAN
our_FPP1
stakeholders_NN
._.
achievement_NOMZ
considering_VBG [PRIV] [WZPRES]
the_DT
manufacturing_GER
expansion_NN
which_WDT [WHSUB]
took_VBD
place_NN
during_PIN
the_DT
year_NN
._.
Our_FPP1
sustainability_NOMZ
efforts_NN
focus_VB
on_PIN
:_:
Social_NN
responsibility_NOMZ
Environmental_NN
management_NOMZ
Employees_NN
Our_FPP1
business_NOMZ
units_NN
are_VPRT [PASS]
required_VBN [SUAV]
to_TO
provide_VB
safe_JJ
Minimising_VBG
the_DT
impact_NN
of_PIN
our_FPP1
activities_NOMZ
on_PIN
the_DT
environment_NOMZ
working_GER
conditions_NOMZ
,_,
plant_NN
and_PHC
equipment_NOMZ
at_PIN
all_QUAN
their_TPP3
facilities_NOMZ
._.
particularly_RB
regarding_VBG
energy_NN
and_PHC
water_NN
use_NN
,_,
waste_NN
,_,
We_FPP1
maintain_VPRT [PUBV]
high_JJ
standards_NN
and_CC
are_VPRT [PASS]
determined_VBN [SUAV] [PRIV]
to_TO
raise_VB
emissions_NN
and_PHC
discharges_NN
._.
them_TPP3
even_RB
higher_RB
through_PIN
sharing_VBG
best_JJ
practice_NN
._.
Business_NOMZ
unit_NN
plans_VPRT
include_VPRT
measures_NN
to_TO
improve_VB
performance_NN
Social_NN
responsibility_NOMZ
monitoring_GER
,_,
enhance_VB
hazard_NN
analysis_NN
and_PHC
risk_NN
assessment_NOMZ
,_,
Employees_NN
Maintaining_VBG [PUBV] [WZPRES]
high_JJ
standards_NN
of_PIN
health_NN
and_PHC
safety_NN
:_:
refine_VB
emergency_NN
plans_NN
and_PHC
business_NOMZ
continuity_NOMZ
plans_NN
and_CC
providing_VBG
training_GER
and_PHC
development_NOMZ
:_:
giving_VBG
people_NN
the_DT
deliver_VPRT
better_JJ
targeted_JJ
training_GER
._.
opportunity_NOMZ
to_TO
let_VB
us_FPP1
know_VB [PRIV]
how_RB [WHCL]
they_TPP3
feel_VPRT [PRIV]
about_IN
working_VBG
for_PIN
Smith_NN
&_CC
Nephew_NN
and_CC
acting_VBG
on_PIN
what_WP
they_TPP3
tell_VPRT
us_FPP1
._.
Our_FPP1
employment_NOMZ
policies_NN
emphasise_VPRT
equality_NOMZ
of_PIN
opportunity_NOMZ
,_,
continuous_JJ
training_GER
and_PHC
development_NOMZ
,_,
open_JJ
communications_NOMZ
,_,
Community_NOMZ
Investing_VBG [WZPRES]
in_PIN
and_CC
working_VBG
with_PIN
the_DT
communities_NOMZ
and_PHC
rewards_NN
appropriate_JJ
to_PIN
local_JJ
markets_NN
._.
Vacancies_NN
are_VPRT [BEMA]
in_PIN
which_WDT [PIRE]
we_FPP1
operate_VPRT
._.
filled_VBN [PASTP]
within_PIN
the_DT
company_NN
wherever_RB
possible_JJ
._.
We_FPP1
treat_VPRT
employees_NN
with_PIN
dignity_NOMZ
and_PHC
fairness_NOMZ
and_CC
have_VPRT
policies_NN
and_PHC
Customers_NN
Educating_VBG [WZPRES]
healthcare_NN
professionals_NN
in_PIN
the_DT
procedures_NN
to_TO
encourage_VB
this_DEMO
culture_NN
._.
We_FPP1
welcome_VPRT
disabled_JJ
techniques_NN
related_VBN [WZPAST]
to_PIN
our_FPP1
product_NN
ranges_NN
and_CC
providing_VBG
people_NN
and_CC
make_VB
every_QUAN
effort_NN
to_TO
retain_VB
any_QUAN
employee_NN
who_WP [WHOBJ]
opportunities_NOMZ
for_PIN
their_TPP3
continuing_VBG
professional_JJ
development_NOMZ
._.
Our_FPP1
new_JJ
Code_NN
of_PIN
Business_NOMZ
Principles_NN
underpins_VPRT
the_DT
high_JJ
standards_NN
we_FPP1
expect_VPRT [PRIV]
from_PIN
our_FPP1
people_NN
._.
Suppliers_NN
Working_VBG [WZPRES]
in_PIN
partnership_NN
with_PIN
suppliers_NN
and_CC
fostering_VBG
open_JJ
,_,
ethical_JJ
relationships_NN
with_PIN
them_TPP3
._.
We_FPP1
recognize_VPRT [PRIV]
the_DT
importance_NN
of_PIN
good_JJ
employee_NN
communications_NOMZ
._.
This_DEMO
year_NN
we_FPP1
have_VPRT [SPAU] [PEAS]
greatly_AMP
improved_VBN
Economic_JJ
impact_NN
groupwide_NN
measurement_NOMZ
and_PHC
data_NN
collection_NOMZ
systems_NN
to_TO
Making_VBG
a_DT
positive_JJ
contribution_NOMZ
to_PIN
society_NN
through_PIN
creating_VBG
monitor_NN
such_JJ
areas_NN
as_IN
employee_NN
satisfaction_NOMZ
,_,
performance_NN
shareholder_NN
value_NN
,_,
paying_VBG
taxes_NN
,_,
investing_VBG
capital_NN
and_PHC
appraisal_NN
,_,
development_NOMZ
and_PHC
career_NN
progression_NN
._.
We_FPP1
have_VPRT
creating_VBG
employment_NOMZ
:_:
maximizing_VBG [PRESP]
the_DT
economic_JJ
benefits_NN
also_RB
set_VBD
up_RP
a_DT
reporting_GER
system_NN
to_TO
collect_VB
data_NN
on_PIN
training_GER
of_PIN
our_FPP1
products_NN
for_PIN
healthcare_NN
providers_NN
,_,
patients_NN
and_CC
throughout_PIN
the_DT
group_NN
._.
These_DEMO
measures_NN
will_PRMD
monitor_VB
progress_NN
those_DEMP
who_WP
pay_VPRT
the_DT
costs_NN
._.
in_PIN
the_DT
coming_VBG
years_NN
and_CC
help_VB
ensure_VB [SUAV] [PRIV]
that_THVC
we_FPP1
target_VPRT
our_FPP1
efforts_NN
in_PIN
the_DT
most_EMPH
effective_JJ
manner_NN
._.
More_EMPH
information_NOMZ
is_VPRT [BEMA]
available_PRED
on_PIN
our_FPP1
website_NN
at_PIN
:_:
12_CD
Smith_NN
&_CC
Nephew_NN
2002_CD
www_NN
._.
com_NN
sustainability2002_NN
In_PIN
2002_CD
we_FPP1
conducted_VBD
our_FPP1
second_JJ
global_JJ
opinion_NN
survey_NN
Suppliers_NN
We_FPP1
treat_VPRT
suppliers_NN
with_PIN
dignity_NOMZ
and_PHC
fairness_NOMZ
,_,
and_ANDC
communicated_VBD
the_DT
results_NN
to_PIN
staff_NN
worldwide_NN
._.
Once_TIME
and_CC
expect_VB [PRIV]
them_TPP3
to_TO
do_VB [PROD]
the_DT
same_JJ
with_PIN
their_TPP3
own_JJ
employees_NN
again_TIME
we_FPP1
had_VBD
over_IN
80_CD
%_NN
of_PIN
employees_NN
participating_VBG [WZPRES]
in_PIN
the_DT
and_CC
suppliers_NN
._.
Our_FPP1
Code_NN
of_PIN
Business_NOMZ
Principles_NN
makes_VPRT
clear_JJ
survey_NN
with_PIN
positive_JJ
scores_NN
in_PIN
all_QUAN
areas_NN
covered_VBD
._.
In_CONJ
addition_NULL
that_TOBJ
we_FPP1
support_VPRT
the_DT
UNs_NN
Universal_NN
Declaration_NOMZ
of_PIN
Human_NN
91_CD
%_NN
of_PIN
respondents_NN
indicated_VBD [PRIV]
that_THVC
they_TPP3
were_VBD [BEMA]
proud_PRED
to_TO
work_VB
Rights_NN
and_PHC
states_NN
that_TOBJ
we_FPP1
will_PRMD [SPAU]
only_DWNT
work_VB
with_PIN
suppliers_NN
for_PIN
the_DT
Smith_NN
&_CC
Nephew_NN
group_NN
._.
Significant_JJ
improvements_NOMZ
who_WP [WHSUB]
adhere_VPRT
to_PIN
business_NOMZ
principles_NN
and_PHC
health_NN
,_,
safety_NN
,_,
social_JJ
over_IN
10_CD
%_NN
increase_NN
in_PIN
scores_NN
in_PIN
many_QUAN
areas_NN
were_VBD [PASS]
seen_VBN [PRIV]
and_CC
environmental_JJ
standards_NN
consistent_JJ
with_PIN
our_FPP1
own_JJ
._.
compared_VBN [PASTP]
with_PIN
the_DT
Year_NN
2000_CD
results_NN
particularly_RB
in_PIN
Specifically_RB
,_,
these_DEMP
prohibit_VPRT
the_DT
use_NN
of_PIN
forced_VBN
,_,
compulsory_JJ
management_NOMZ
style_NN
,_,
communication_NOMZ
with_PIN
employees_NN
,_,
or_CC
child_NN
labor_NN
._.
anticipating_VBG [PRIV]
change_NN
and_CC
the_DT
way_NN
people_NN
feel_VPRT [PRIV]
about_IN
their_TPP3
job_NN
,_,
confirming_VBG [PUBV]
that_THVC
we_FPP1
have_VPRT [PEAS]
made_VBN
good_JJ
progress_NN
in_PIN
all_QUAN
areas_NN
Economic_JJ
impact_NN
over_IN
the_DT
past_JJ
two_CD
years_NN
._.
But_CC
we_FPP1
still_RB
have_VPRT
work_NN
to_TO
do_VB [PROD]
:_:
Our_FPP1
business_NOMZ
policies_NN
aim_VPRT
to_TO
achieve_VB
long-term_JJ
growth_NN
and_PHC
scores_NN
for_PIN
questions_NOMZ
about_IN
promotion_NOMZ
and_PHC
reward_NN
were_VBD
profits_NN
which_WDT [WHOBJ]
in_PIN
turn_NN
bring_VPRT
continued_JJ
economic_JJ
benefits_NN
to_TO
still_RB
lower_JJ
than_PIN
we_FPP1
would_PRMD
like_VB
and_CC
this_DEMP
will_PRMD
stimulate_VB
action_NOMZ
shareholders_NN
,_,
employees_NN
,_,
suppliers_NN
and_CC
local_JJ
communities_NOMZ
._.
Our_FPP1
sustainable_JJ
development_NOMZ
depends_VPRT
ultimately_RB
on_PIN
our_FPP1
ability_NOMZ
to_TO
provide_VB
a_DT
satisfactory_JJ
return_NN
:_:
in_PIN
2002_CD
we_FPP1
generated_VBD
The_DT
communications_NOMZ
functions_NOMZ
at_PIN
our_FPP1
group_NN
head_NN
office_NN
,_,
an_DT
operating_GER
return_NN
on_PIN
capital_NN
employed_VBN [WZPAST]
of_PIN
29_CD
%_NN
._.
group_NN
research_NN
center_NN
and_CC
global_JJ
business_NOMZ
units_NN
work_VPRT
closely_RB
with_PIN
the_DT
Human_NN
Resources_NN
departments_NOMZ
at_PIN
each_QUAN
We_FPP1
continue_VPRT
to_TO
invest_VB
in_PIN
comprehensive_JJ
R&D_NN
programs_NN
site_NN
on_PIN
all_QUAN
forms_NN
of_PIN
internal_JJ
communication_NOMZ
._.
Our_FPP1
linked_VBN
focused_VBN
on_PIN
delivering_VBG
better_JJ
outcomes_NN
for_PIN
patients_NN
and_PHC
business_NOMZ
unit_NN
and_CC
corporate_JJ
intranets_NN
are_VPRT
increasingly_RB
well_RB
improvements_NOMZ
in_PIN
application_NOMZ
and_PHC
use_NN
for_PIN
practitioners_NN
._.
used_VBN
,_,
allowing_VBG [SUAV]
easy_JJ
two-way_JJ
communication_NOMZ
worldwide_NN
and_CC
Importantly_RB
,_,
we_FPP1
also_RB
aim_VPRT
to_TO
deliver_VB
overall_JJ
cost_NN
savings_GER
increasing_VBG [WZPRES]
peoples_NN
awareness_NOMZ
of_PIN
financial_JJ
,_,
economic_JJ
and_CC
to_PIN
healthcare_NN
systems_NN
through_PIN
such_JJ
benefits_NN
as_IN
reduced_JJ
market_NN
factors_NN
affecting_VBG [WZPRES]
company_NN
performance_NN
._.
Electronic_JJ
dressing_VBG
changes_NN
and_CC
shorter_JJ
operating_GER
theater_NN
times_NN
._.
communication_NOMZ
in_PIN
general_JJ
continues_VPRT
to_TO
reduce_VB
internal_JJ
Our_FPP1
products_NN
seek_VPRT
to_TO
reduce_VB
patients_NN
time_NN
in_PIN
hospital_NN
paperwork_NN
throughout_PIN
the_DT
company_NN
._.
and_ANDC
return_VB
them_TPP3
to_PIN
health_NN
faster_RB
,_,
potentially_RB
improving_VBG
their_TPP3
productivity_NOMZ
and_CC
bringing_VBG
broader_JJ
social_JJ
and_CC
Community_NOMZ
We_FPP1
recognize_VPRT [PRIV]
a_DT
strong_JJ
obligation_NOMZ
to_TO
contribute_VB
economic_JJ
benefits_NN
._.
to_PIN
the_DT
communities_NOMZ
in_PIN
which_WDT [PIRE]
we_FPP1
operate_VPRT
._.
We_FPP1
encourage_VPRT
and_PHC
support_VPRT
employees_NN
at_PIN
all_QUAN
levels_NN
who_WP [WHSUB]
undertake_VPRT
community_NOMZ
work_NN
,_,
providing_VBG
resources_NN
and_CC
paid_VBN
time_NN
off_PIN
to_TO
participate_VB
in_PIN
projects_NN
._.
We_FPP1
support_VPRT
a_DT
range_NN
of_PIN
charitable_JJ
causes_NN
,_,
mainly_RB
at_PIN
local_JJ
level_NN
,_,
by_PIN
donations_NOMZ
of_PIN
money_NN
,_,
gifts_NN
in_PIN
kind_NN
and_PHC
employee_NN
time_NN
._.
The_DT
company_NN
is_VPRT [BEMA]
a_DT
member_NN
of_PIN
UK_NN
Business_NOMZ
in_PIN
the_DT
Community_NOMZ
and_CC
we_FPP1
are_VPRT [PASS]
committed_VBN
to_PIN
corporate_JJ
community_NOMZ
involvement_NOMZ
across_PLACE
the_DT
whole_JJ
group_NN
wherever_RB
practical_JJ
._.
Of_PIN
course_NN
,_,
we_FPP1
are_VPRT [SPAU] [PASS]
also_RB
committed_VBN
to_TO
meeting_VBG
our_FPP1
community_NOMZ
obligations_NOMZ
under_IN
the_DT
law_NN
._.
Examples_NN
of_PIN
the_DT
programs_NN
we_FPP1
support_VPRT
around_PLACE
our_FPP1
manufacturing_GER
sites_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
the_DT
Performance_NN
section_NOMZ
of_PIN
the_DT
Sustainability_NOMZ
Report_NN
on_PIN
our_FPP1
website_NN
._.
In_PIN
2002_CD
our_FPP1
direct_JJ
donations_NOMZ
to_PIN
charitable_JJ
and_CC
community_NOMZ
activities_NOMZ
totalled_VBD
804,000_CD
,_,
of_PIN
which_WDT [PIRE]
400,000_CD
went_VBD
to_PIN
the_DT
Smith_NN
&_CC
Nephew_NN
Foundation_NOMZ
to_TO
fund_VB
individual_JJ
research_NN
for_PIN
doctors_NN
and_PHC
nurses_NN
._.
During_PIN
the_DT
year_NN
,_,
we_FPP1
restructured_VBD
the_DT
Foundation_NOMZ
to_TO
focus_VB
solely_RB
on_PIN
nursing_GER
research_NN
where_RB
it_PIT
makes_VPRT
a_DT
major_JJ
contribution_NOMZ
in_PIN
the_DT
UK_NN
._.
We_FPP1
again_TIME
made_VBD
no_SYNE
political_JJ
contributions_NOMZ
in_PIN
2002_CD
._.
Customers_NN
Educational_NN
support_NN
to_PIN
the_DT
medical_JJ
community_NOMZ
which_WDT [WHOBJ]
we_FPP1
serve_VPRT
is_VPRT [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
the_DT
way_NN
we_FPP1
do_VPRT [PROD]
business_NOMZ
._.
All_QUAN
three_CD
of_PIN
our_FPP1
business_NOMZ
units_NN
run_VPRT
extensive_JJ
educational_JJ
programs_NN
ranging_VBG [WZPRES]
from_PIN
seminars_NN
and_CC
dedicated_VBN
training_GER
facilities_NOMZ
to_PIN
web-based_JJ
information_NOMZ
sites_NN
._.
During_PIN
2002_CD
our_FPP1
Endoscopy_JJ
business_NOMZ
alone_RB
hosted_VBD
144_CD
courses_NN
,_,
training_GER
over_IN
1,700_CD
surgeons_NN
._.
Smith_NN
&_CC
Nephew_NN
2002_CD
13_CD
Corporate_JJ
governance_NN
The_DT
Board_NN
is_VPRT [PASS]
committed_VBN
to_PIN
the_DT
highest_JJ
standards_NN
of_PIN
Shareholders_NN
corporate_JJ
governance_NN
and_CC
considers_VPRT [PRIV]
that_THVC
the_DT
company_NN
The_DT
group_NN
issues_NN
summary_NN
financial_JJ
statements_NOMZ
in_PIN
place_NN
of_PIN
has_VPRT [PEAS]
complied_VBN
throughout_PIN
the_DT
year_NN
with_PIN
the_DT
Combined_VBN
full_JJ
annual_JJ
accounts_NN
unless_COND
shareholders_NN
request_VPRT [SUAV]
the_DT
latter_JJ
._.
Code_NN
of_PIN
Best_JJ
Practice_NN
on_PIN
Corporate_JJ
Governance_NN
._.
The_DT
summary_NN
financial_JJ
statement_NOMZ
is_VPRT [BYPA]
received_VBN
by_PIN
over_IN
90_CD
%_NN
The_DT
Board_NN
of_PIN
shareholders_NN
._.
At_PIN
the_DT
half_NN
year_NN
,_,
an_DT
interim_JJ
report_NN
is_VPRT [PASS]
sent_VBN
The_DT
Board_NN
meets_VPRT
regularly_RB
during_PIN
the_DT
year_NN
and_CC
is_VPRT [BEMA]
to_PIN
all_QUAN
shareholders_NN
._.
A_DT
copy_NN
of_PIN
the_DT
full_JJ
annual_JJ
accounts_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
strategic_JJ
direction_NOMZ
,_,
policies_NN
and_CC
overall_JJ
available_JJ
on_PIN
the_DT
Smith_NN
&_CC
Nephew_NN
website_NN
along_IN
with_PIN
press_NN
management_NOMZ
of_PIN
the_DT
group_NN
._.
There_EX
is_VPRT
a_DT
clear_JJ
division_NN
of_PIN
releases_NN
,_,
institutional_JJ
presentations_NOMZ
and_CC
audio_JJ
webcasts_NN
._.
responsibilities_NOMZ
between_PIN
the_DT
Chairman_NN
and_PHC
Chief_NN
Executive_NN
._.
There_EX
are_VPRT
regular_JJ
dialogues_NN
with_PIN
individual_JJ
institutional_JJ
The_NN
Board_NN
consists_VPRT
of_PIN
an_DT
independent_JJ
non-executive_JJ
shareholders_NN
,_,
together_RB
with_PIN
results_NN
presentations_NOMZ
twice_RB
a_DT
Chairman_NN
,_,
two_CD
executive_JJ
directors_NN
and_CC
six_CD
independent_JJ
year_NN
._.
There_EX
is_VPRT
an_DT
opportunity_NOMZ
for_PIN
individual_JJ
shareholders_NN
to_PIN
non-executive_JJ
directors_NN
._.
All_QUAN
directors_NN
have_VPRT
full_JJ
and_PHC
timely_JJ
question_NOMZ
directors_NN
at_PIN
the_DT
AGM_NN
and_CC
the_DT
company_NN
regularly_RB
access_NN
to_PIN
all_QUAN
relevant_JJ
information_NOMZ
and_CC
independent_JJ
responds_VPRT
to_PIN
letters_NN
from_PIN
shareholders_NN
on_PIN
a_DT
range_NN
of_PIN
issues_NN
._.
Non-executive_JJ
directors_NN
meet_VPRT
regularly_RB
without_PIN
management_NOMZ
in_PIN
attendance_NN
and_CC
appropriate_JJ
Risk_NN
management_NOMZ
&_CC
internal_JJ
control_NN
induction_NOMZ
programs_NN
are_VPRT [PASS]
offered_VBN
to_PIN
new_JJ
directors_NN
._.
The_DT
Board_NN
is_VPRT [BEMA]
responsible_PRED
for_PIN
the_DT
maintenance_NN
of_PIN
the_DT
groups_NN
systems_NN
of_PIN
risk_NN
management_NOMZ
and_CC
internal_JJ
control_NN
and_CC
for_PIN
The_DT
Board_NN
is_VPRT [BYPA]
assisted_VBN
by_PIN
the_DT
following_VBG
committees_NN
:_:
reviewing_VBG [PRESP]
their_TPP3
effectiveness_NOMZ
._.
An_DT
ongoing_JJ
process_NN
has_VPRT [PEAS]
been_VBN [BEMA]
in_PIN
place_NN
for_PIN
the_DT
full_JJ
year_NN
identifying_VBG [WZPRES]
,_,
evaluating_VBG
and_PHC
managing_VBG
The_DT
Audit_NN
Committee_NN
The_NN
Audit_NN
Committee_NN
monitors_VPRT
key_JJ
risks_NN
through_PIN
a_DT
Risk_NN
Committee_NN
which_WDT [WHSUB]
reports_VPRT [PUBV]
to_PIN
the_DT
the_DT
operation_NOMZ
and_PHC
effectiveness_NOMZ
of_PIN
internal_JJ
financial_JJ
controls_NN
Board_NN
annually_RB
,_,
and_ANDC
by_PIN
a_DT
system_NN
of_PIN
functional_JJ
reports_NN
to_TO
and_CC
ensures_VPRT [SUAV] [PRIV]
that_THVC
the_DT
accounts_NN
meet_VPRT
statutory_JJ
and_PHC
other_JJ
the_DT
Board_NN
and_CC
the_DT
review_NN
of_PIN
internal_JJ
financial_JJ
controls_NN
by_PIN
requirements_NOMZ
._.
It_PIT
selects_VPRT
,_,
determines_VPRT [SUAV] [PRIV]
the_DT
fees_NN
and_CC
reviews_VPRT
the_DT
Audit_NN
Committee_NN
._.
the_DT
performance_NN
,_,
independence_NN
and_PHC
objectivity_NOMZ
of_PIN
the_DT
auditors_NN
._.
All_QUAN
non-audit_JJ
work_NN
is_VPRT [BEMA]
pre-approved_PRED
by_PIN
These_DEMO
procedures_NN
are_VPRT [PASS]
designed_VBN
to_TO
identify_VB
and_PHC
manage_VB
the_DT
committee_NN
._.
those_DEMO
risks_NN
that_TSUB
could_POMD [SPAU]
adversely_RB
impact_VB
the_DT
achievement_NOMZ
of_PIN
the_DT
groups_NN
objectives_NN
._.
Whilst_OSUB
they_TPP3
do_VPRT
not_XX0
provide_VB
The_DT
Remuneration_NOMZ
Committee_NN
The_NN
Remuneration_NOMZ
absolute_JJ
assurance_NN
against_PIN
material_NN
misstatements_NOMZ
or_CC
loss_NN
,_,
Committee_NN
sets_VPRT
the_DT
pay_NN
and_PHC
benefits_NN
of_PIN
the_DT
executive_NN
the_DT
directors_NN
,_,
following_VBG [PRESP]
a_DT
review_NN
of_PIN
the_DT
systems_NN
described_VBD
directors_NN
and_PHC
members_NN
of_PIN
the_DT
Group_NN
Executive_NN
Committee_NN
,_,
are_VPRT [BEMA]
of_PIN
the_DT
opinion_NN
that_TOBJ
proper_JJ
systems_NN
of_PIN
risk_NN
management_NOMZ
approves_VPRT
their_TPP3
main_JJ
terms_NN
of_PIN
employment_NOMZ
and_CC
determines_VPRT [SUAV] [PRIV]
and_CC
internal_JJ
control_NN
are_VPRT [BEMA]
in_PIN
place_NN
within_PIN
the_DT
group_NN
._.
share_NN
options_NOMZ
and_CC
long-term_JJ
incentive_NN
arrangements_NOMZ
._.
It_PIT
also_RB
reviews_VPRT
management_NOMZ
succession_NN
planning_GER
._.
Share_NN
capital_NN
The_DT
company_NN
has_VPRT [PEAS]
been_VBN [PASS]
informed_VBN
of_PIN
the_DT
following_VBG
interests_NN
The_DT
Nominations_NOMZ
Committee_NN
The_DT
Nominations_NOMZ
Committee_NN
in_PIN
its_PIT
ordinary_JJ
share_NN
capital_NN
as_IN
at_PIN
7_CD
February_NN
2003_CD
:_:
oversees_VPRT
plans_NN
for_PIN
Board_NN
succession_NN
and_CC
recommends_VPRT [SUAV]
appointments_NOMZ
to_PIN
the_DT
Board_NN
._.
AXA_NN
Investment_NOMZ
Management_NOMZ
9.0_CD
%_NN
Fidelity_NOMZ
7.1_CD
%_NN
The_DT
Group_NN
Executive_NN
Committee_NN
The_NN
Group_NN
Executive_NN
Legal_NN
&_CC
General_NN
Investment_NOMZ
Management_NOMZ
3.4_CD
%_NN
Committee_NN
assists_VPRT
the_DT
Chief_NN
Executive_NN
in_PIN
the_DT
management_NOMZ
of_PIN
the_DT
group_NN
._.
At_PIN
the_DT
AGM_NN
,_,
the_DT
company_NN
will_PRMD
be_VB
seeking_VBG
a_DT
renewal_NN
of_PIN
its_PIT
current_JJ
permission_NN
from_PIN
shareholders_NN
to_TO
purchase_VB
its_PIT
own_JJ
The_DT
terms_NN
of_PIN
reference_NN
of_PIN
the_DT
Audit_NN
,_,
Remuneration_NOMZ
and_PHC
shares_NN
._.
No_SYNE
shares_NN
have_VPRT [PEAS]
been_VBN [PASS]
purchased_VBN
or_CC
contracted_VBN
for_PIN
Nominations_NOMZ
Committees_NN
may_POMD
be_VB [PASS]
found_VBN [PRIV]
at_PIN
www_NN
._.
smithor_NN
are_VPRT [BEMA]
the_DT
subject_NN
of_PIN
an_DT
option_NOMZ
under_IN
the_DT
expiring_VBG
authority_NOMZ
._.
Auditors_NN
Membership_NN
of_PIN
Board_NN
committees_NN
and_CC
of_PIN
the_DT
Group_NN
Ernst_NN
&_CC
Young_NN
LLP_NN
have_VPRT [PEAS]
expressed_VBN
their_TPP3
willingness_NOMZ
Executive_NN
Committee_NN
is_VPRT [PASS]
shown_VBN [PRIV]
with_PIN
the_DT
biographical_JJ
to_TO
continue_VB
as_IN
auditors_NN
and_CC
a_DT
resolution_NOMZ
proposing_VBG [SUAV] [WZPRES]
their_TPP3
details_NN
of_PIN
directors_NN
on_PIN
pages_NN
10_CD
and_CC
11_CD
._.
reappointment_NOMZ
will_PRMD
be_VB [PASS]
put_VBN
to_PIN
the_DT
AGM_NN
._.
Directors_NN
All_QUAN
directors_NN
are_VPRT [BEMA]
subject_PRED
to_PIN
re-election_NOMZ
every_QUAN
three_CD
years_NN
,_,
and_ANDC
in_PIN
accordance_NN
with_PIN
the_DT
Articles_NN
of_PIN
Association_NOMZ
,_,
Dudley_NN
Eustace_NN
and_PHC
Peter_NN
Hooley_NN
retire_VB
by_PIN
rotation_NOMZ
and_CC
,_,
being_VBG [BEMA]
eligible_JJ
offer_NN
themselves_TPP3
for_PIN
re-election_NOMZ
at_PIN
the_DT
forthcoming_JJ
AGM_NN
._.
Sir_NN
Timothy_NN
Lankester_NN
will_PRMD
be_VB
retiring_VBG
at_PIN
the_DT
AGM_NN
but_CC
will_PRMD
not_XX0
be_VB
offering_VBG
himself_TPP3
for_PIN
re-election_NOMZ
._.
No_SYNE
director_NN
had_VBD
a_DT
material_NN
beneficial_JJ
interest_NN
in_PIN
any_QUAN
contract_NN
involving_VBG [WZPRES]
the_DT
company_NN
or_CC
its_PIT
subsidiaries_NN
in_PIN
2002_CD
._.
14_CD
Smith_NN
&_CC
Nephew_NN
2002_CD
Summary_NN
remuneration_NOMZ
report_NN
Remuneration_NOMZ
policy_NN
The_DT
Remuneration_NOMZ
Committee_NN
policy_NN
for_PIN
this_DEMP
and_CC
future_JJ
years_NN
is_VPRT
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
remuneration_NOMZ
is_VPRT [BEMA]
sufficiently_RB
competitive_PRED
to_TO
attract_VB
,_,
retain_VB
and_PHC
motivate_VB
executive_JJ
directors_NN
and_PHC
Group_NN
Executive_NN
Committee_NN
members_NN
of_PIN
a_DT
calibre_NN
that_TSUB
meets_VPRT
the_DT
groups_NN
needs_VPRT
to_TO
achieve_VB
its_PIT
performance_NN
against_PIN
financial_JJ
objectives_NN
and_CC
relevant_JJ
competitors_NN
practice_NN
._.
Remuneration_NOMZ
throughout_PIN
the_DT
group_NN
is_VPRT [PASS]
designed_VBN
to_TO
be_VB [BEMA]
competitive_PRED
in_PIN
the_DT
country_NN
of_PIN
employment_NOMZ
._.
The_DT
committee_NN
gives_VPRT
full_JJ
consideration_NOMZ
to_PIN
the_DT
requirements_NOMZ
in_PIN
Schedule_NN
A_NN
of_PIN
the_DT
Combined_NN
Code_NN
._.
Directors_NN
incentive_NN
plans_VPRT
Executive_NN
directors_NN
participate_VB
in_PIN
an_DT
annual_JJ
bonus_NN
scheme_NN
based_VBN [WZPAST]
on_PIN
annual_JJ
growth_NN
in_PIN
adjusted_JJ
earnings_GER
per_PIN
share_NN
after_IN
deducting_VBG
goodwill_NN
amortisation_NOMZ
and_PHC
return_NN
on_PIN
capital_NN
employed_VBN
,_,
and_ANDC
in_PIN
a_DT
long-term_JJ
incentive_NN
plan_NN
LTIP_NN
based_VBN [WZPAST]
on_PIN
the_DT
companys_NN
total_JJ
shareholder_NN
return_NN
TSR_NN
in_PIN
relation_NOMZ
to_PIN
41_CD
UK_NN
listed_VBN
manufacturing_GER
companies_NN
with_PIN
substantial_JJ
international_JJ
activities_NOMZ
,_,
and_ANDC
growth_NN
in_PIN
earnings_GER
per_PIN
share_NN
over_IN
a_DT
three_CD
year_NN
period_NN
._.
The_DT
performance_NN
conditions_NOMZ
were_VBD [PASS]
identified_VBN
as_IN
those_DEMP
which_WDT
represented_VBD
a_DT
fair_JJ
measure_NN
of_PIN
the_DT
companys_NN
performance_NN
and_CC
would_PRMD
reflect_VB [PRIV]
increase_NN
in_PIN
shareholder_NN
value_NN
._.
The_DT
companys_NN
TSR_NN
performance_NN
and_CC
its_PIT
performance_NN
relative_JJ
to_PIN
the_DT
comparator_NN
group_NN
is_VPRT [BYPA]
monitored_VBN
by_PIN
independent_JJ
consultants_NN
._.
Total_JJ
outstanding_JJ
conditional_JJ
awards_NN
of_PIN
shares_NN
under_IN
the_DT
LTIP_NN
are_VPRT
:_:
Christopher_NN
ODonnell_NN
386,488_CD
2001_CD
448,649_CD
and_CC
Peter_NN
Hooley_NN
236,824_CD
2001_CD
282,965_CD
._.
For_PIN
the_DT
three_CD
year_NN
plan_NN
period_NN
commencing_VBG [WZPRES]
2000_CD
the_DT
companys_NN
TSR_NN
of_PIN
147.36_CD
%_NN
was_VBD [PASS]
ranked_VBN
first_RB
in_PIN
the_DT
comparator_NN
group_NN
and_CC
the_DT
earnings_GER
per_PIN
share_NN
performance_NN
criterion_NN
was_VBD [PASS]
met_VBN
,_,
enabling_VBG [PRESP]
the_DT
plan_NN
participants_NN
to_TO
be_VB [BEMA]
eligible_PRED
for_PIN
100_CD
%_NN
of_PIN
the_DT
shares_NN
conditionally_RB
awarded_VBN
in_PIN
2000_CD
._.
As_CONJ
a_NULL
result_NULL
,_,
on_PIN
7_CD
February_NN
2003_CD
,_,
Christopher_NN
ODonnell_NN
became_VBD
entitled_VBN
to_PIN
155,065_CD
shares_NN
and_PHC
Peter_NN
Hooley_NN
entitled_VBD
to_PIN
96,916_CD
shares_NN
which_WDT [WHSUB]
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
outstanding_JJ
conditional_JJ
awards_NN
of_PIN
shares_NN
above_PLACE
._.
Executive_NN
directors_NN
were_VBD [BEMA]
last_PRED
granted_VBN [SUAV]
options_NOMZ
under_IN
executive_JJ
share_NN
option_NOMZ
schemes_NN
in_PIN
1996_CD
which_WDT
were_VBD [BEMA]
not_XX0
subject_PRED
to_PIN
performance_NN
conditions_NOMZ
,_,
but_CC
under_IN
the_DT
LTIP_NN
,_,
shares_NN
that_TSUB
have_VPRT [PEAS]
vested_VBN
may_POMD
be_VB [PASS]
taken_VBN
in_PIN
the_DT
form_NN
of_PIN
nil-cost_JJ
options_NOMZ
and_CC
exercised_VBN
at_PIN
a_DT
later_TIME
date_NN
._.
UK_NN
directors_NN
are_VPRT [BEMA]
eligible_PRED
to_TO
participate_VB
in_PIN
the_DT
savings_GER
related_VBN
share_NN
option_NOMZ
scheme_NN
._.
As_IN
a_DT
component_NN
company_NN
of_PIN
the_DT
FTSE_NN
100_CD
index_NN
,_,
a_DT
graph_NN
of_PIN
the_DT
companys_NN
TSR_NN
performance_NN
compared_VBN [WZPAST]
to_PIN
that_DEMO
of_PIN
the_DT
TSR_NN
of_PIN
the_DT
index_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
on_PIN
page_NN
2_CD
._.
Service_NN
contracts_NN
Executive_NN
directors_NN
,_,
in_PIN
line_NN
with_PIN
group_NN
policy_NN
,_,
have_VPRT
notice_NN
periods_NN
of_PIN
12_CD
months_NN
._.
All_QUAN
new_JJ
appointments_NOMZ
are_VPRT [PASS]
intended_VBN [SUAV]
to_TO
have_VB
12_CD
months_NN
notice_NN
periods_NN
,_,
but_CC
it_PIT
is_VPRT [PASS]
recognized_VBN [PRIV]
that_THVC
for_PIN
some_QUAN
appointments_NOMZ
a_DT
longer_JJ
period_NN
may_POMD [SPAU]
initially_TIME
be_VB [BEMA]
necessary_PRED
for_PIN
competitive_JJ
reasons_NN
,_,
reducing_VBG [PRESP]
to_PIN
12_CD
months_NN
thereafter_RB
._.
Christopher_NN
ODonnell_NN
and_PHC
Peter_NN
Hooley_NN
have_VPRT
contracts_NN
terminable_JJ
by_PIN
the_DT
company_NN
on_PIN
not_XX0
more_EMPH
than_PIN
12_CD
months_NN
notice_NN
and_CC
by_PIN
the_DT
director_NN
on_PIN
6_CD
months_NN
notice_NN
._.
Termination_NOMZ
of_PIN
the_DT
contract_NN
by_PIN
the_DT
company_NN
would_PRMD
entitle_VB
the_DT
executive_NN
directors_NN
to_PIN
12_CD
months_NN
basic_JJ
salary_NN
,_,
bonus_NN
at_PIN
target_NN
of_PIN
30_CD
%_NN
,_,
a_DT
contribution_NOMZ
of_PIN
30_CD
%_NN
of_PIN
salary_NN
to_TO
reflect_VB [PRIV]
the_DT
loss_NN
of_PIN
pension_NN
benefits_NN
,_,
an_DT
amount_NN
to_TO
cover_VB
other_JJ
benefits_NN
and_CC
a_DT
time_NN
apportionment_NOMZ
of_PIN
the_DT
LTIP_NN
entitlement_NOMZ
._.
Non-executive_JJ
directors_NN
do_VPRT
not_XX0
have_VB
service_NN
contracts_NN
and_CC
are_VPRT [SPAU] [PASS]
normally_RB
appointed_VBN
for_PIN
terms_NN
of_PIN
three_CD
years_NN
terminable_JJ
at_PIN
will_PRMD
,_,
without_PIN
notice_NN
by_PIN
either_CC
the_DT
company_NN
or_CC
the_DT
director_NN
and_CC
without_PIN
compensation_NOMZ
._.
Their_TPP3
remuneration_NOMZ
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
the_DT
Nominations_NOMZ
Committee_NN
._.
Directors_NN
emoluments_NOMZ
and_PHC
share_NN
interests_NN
Total_JJ
emoluments_NOMZ
Share_NN
interests_NN
2002_CD
2001_CD
31_CD
December_NN
2002_CD
1_CD
January_NN
2002 000 000_CD
Shares_NN
Options_NOMZ
Shares_NN
Options_NOMZ
Chairman_NN
:_:
D._NN
G._NN
Eustace_NN
170_CD
170_CD
49,679_CD
40,909_CD
Executive_NN
:_:
C._NN
J._NN
ODonnell_NN
890 790 122_CD
,136_CD
517,495_CD
120,703_CD
331,263_CD
P._NN
Hooley_NN
583 545 111_CD
,571_CD
450,682_CD
58,789_CD
423,723_CD
NonSir_NN
Timothy_NN
Lankester_NN
30_CD
30_CD
6,096_CD
6,035_CD
executive_NN
:_:
Dr_NN
R._NN
W._NN
H._NN
Stomberg_NN
30_CD
30_CD
6,945_CD
6,864_CD
W._NN
D._NN
Knowlton_NN
30_CD
30_CD
12,501_CD
7,501_CD
R._NN
fide_NN
Schutter_NN
30_CD
30_CD
200,000_CD
100,000_CD
Dr_NN
P._NN
Kirby_NN
from_PIN
1_CD
March_NN
2002_CD
25_CD
B._NN
Larcombe_NN
from_PIN
1_CD
March_NN
2002_CD
25_CD
Sir_NN
Anthony_NN
Cleaver_NN
to_PIN
28_CD
Feb_NN
2002_CD
5_CD
30_CD
Sir_NN
Brian_NN
Pearse_NN
to_PIN
28_CD
Feb_NN
2002_CD
5_CD
30_CD
1,823_CD
1,685_CD
Inclusive_NN
of_PIN
salaries_NN
and_PHC
fees_NN
,_,
benefits_NN
,_,
annual_JJ
bonus_NN
and_PHC
pension_NN
entitlements_NOMZ
._.
Profits_NN
on_PIN
exercise_NN
of_PIN
share_NN
options_NOMZ
were_VBD [BEMA]
211,950_CD
:_:
Peter_NN
Hooley_NN
211,950_CD
2001_CD
197,542_CD
:_:
Christopher_NN
ODonnell_NN
22,171_CD
,_,
Peter_NN
Hooley_NN
175,371_CD
._.
Smith_NN
&_CC
Nephew_NN
2002_CD
15_CD
Auditors_NN
statement_NOMZ
Independent_NN
auditors_NN
statement_NOMZ
to_PIN
the_DT
members_NN
of_PIN
Smith_NN
&_CC
Nephew_NN
plc_NN
We_FPP1
have_VPRT [PEAS]
examined_VBN
the_DT
groups_NN
summary_NN
financial_JJ
statement_NOMZ
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
which_WDT
comprises_VPRT
summary_NN
group_NN
profit_NN
and_PHC
loss_NN
account_NN
,_,
summary_NN
group_NN
balance_NN
sheet_NN
and_PHC
summary_NN
group_NN
cash_NN
flow_NN
statement_NOMZ
._.
Respective_JJ
responsibilities_NOMZ
of_PIN
directors_NN
and_PHC
auditors_NN
The_DT
directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
preparing_VBG
the_DT
report_NN
to_PIN
shareholders_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
in_PIN
accordance_NN
with_PIN
applicable_JJ
law_NN
._.
This_DEMO
report_NN
has_VPRT [PEAS]
been_VBN [PASS]
prepared_VBN
for_PIN
the_DT
members_NN
of_PIN
the_DT
company_NN
pursuant_JJ
to_PIN
Section_NOMZ
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
the_DT
Act_NN
and_CC
for_PIN
no_SYNE
other_JJ
purpose_NN
._.
No_SYNE
person_NN
is_VPRT [PASS]
entitled_VBN
to_TO
rely_VB
on_PIN
this_DEMO
report_NN
unless_COND
such_JJ
person_NN
:_:
i_FPP1
is_VPRT [BEMA]
a_DT
person_NN
who_WP [WHSUB]
is_VPRT [PASS]
entitled_VBN
to_TO
rely_VB
on_PIN
this_DEMO
report_NN
by_PIN
virtue_NN
of_PIN
and_CC
for_PIN
the_DT
purpose_NN
of_PIN
the_DT
Act_NN
:_:
or_CC
ii_FW
has_VPRT [PEAS]
been_VBN [SPAU] [PASS]
expressly_RB
authorised_VBN
to_TO
do_VB
so_RB
by_PIN
our_FPP1
prior_JJ
written_VBN [PUBV]
consent_NN
._.
Save_NN
as_IN
above_PLACE
,_,
we_FPP1
do_VPRT
not_XX0
accept_VB [PRIV]
responsibility_NOMZ
for_PIN
this_DEMO
report_NN
to_PIN
any_QUAN
other_JJ
person_NN
or_CC
for_PIN
any_QUAN
other_JJ
purpose_NN
and_CC
we_FPP1
hereby_VPRT
expressly_RB
disclaim_VB
any_QUAN
and_CC
all_QUAN
such_JJ
liability_NOMZ
._.
Our_FPP1
responsibility_NOMZ
is_VPRT
to_TO
report_VB [PUBV]
to_PIN
you_SPP2
our_FPP1
opinion_NN
on_PIN
the_DT
consistency_NN
of_PIN
the_DT
summary_NN
financial_JJ
statement_NOMZ
within_PIN
the_DT
report_NN
to_PIN
shareholders_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
with_PIN
the_DT
full_JJ
annual_JJ
accounts_NN
,_,
directors_NN
report_NN
and_PHC
remuneration_NOMZ
report_NN
,_,
and_ANDC
its_PIT
compliance_NN
with_PIN
the_DT
relevant_JJ
requirements_NOMZ
of_PIN
section_NOMZ
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
the_DT
regulations_NOMZ
made_VBD
thereunder_RB
._.
We_FPP1
also_RB
read_VBD
the_DT
other_JJ
information_NOMZ
contained_VBN [WZPAST]
in_PIN
the_DT
report_NN
to_PIN
the_DT
shareholders_NN
and_PHC
summary_NN
financial_JJ
statement_NOMZ
and_CC
consider_VB [PRIV]
the_DT
implications_NOMZ
for_PIN
our_FPP1
report_NN
if_COND
we_FPP1
become_VPRT
aware_JJ
of_PIN
any_QUAN
apparent_JJ
misstatements_NOMZ
or_CC
material_NN
inconsistencies_NN
with_PIN
the_DT
summary_NN
financial_JJ
statement_NOMZ
._.
Basis_NN
of_PIN
opinion_NN
We_FPP1
conducted_VBD
our_FPP1
examination_NOMZ
in_PIN
accordance_NN
with_PIN
Bulletin_NN
1999_CD
6_CD
The_DT
auditors_NN
statement_NOMZ
on_PIN
the_DT
summary_NN
financial_JJ
statement_NOMZ
issued_VBN [WZPAST]
by_PIN
the_DT
Auditing_GER
Practices_NN
Board_NN
for_PIN
use_NN
in_PIN
the_DT
United_NN
Kingdom_NN
._.
Opinion_NN
In_PIN
our_FPP1
opinion_NN
the_DT
summary_NN
financial_JJ
statement_NOMZ
is_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
full_JJ
annual_JJ
accounts_NN
,_,
directors_NN
report_NN
and_PHC
remuneration_NOMZ
report_NN
of_PIN
Smith_NN
&_CC
Nephew_NN
plc_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
and_CC
complies_VPRT
with_PIN
the_DT
applicable_JJ
requirements_NOMZ
of_PIN
section_NOMZ
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
and_ANDC
regulations_NOMZ
made_VBD
thereunder_RB
._.
Ernst_NN
&_CC
Young_NN
LLP_NN
Registered_NN
auditor_NN
London_NN
,_,
7_CD
February_NN
2003_CD
This_DEMO
summary_NN
financial_JJ
statement_NOMZ
is_VPRT [BEMA]
a_DT
summary_NN
of_PIN
information_NOMZ
in_PIN
the_DT
groups_NN
full_JJ
annual_JJ
accounts_NN
and_CC
was_VBD [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
on_PIN
7_CD
February_NN
2003_CD
and_CC
signed_VBN
on_PIN
its_PIT
behalf_NN
by_PIN
Dudley_NN
Eustace_NN
,_,
Christopher_NN
ODonnell_NN
and_PHC
Peter_NN
Hooley_NN
._.
It_PIT
does_VPRT
not_XX0
contain_VB
sufficient_JJ
information_NOMZ
to_TO
allow_VB [SUAV]
a_DT
full_JJ
understanding_GER
of_PIN
the_DT
results_NN
of_PIN
the_DT
group_NN
and_PHC
state_NN
of_PIN
affairs_NN
of_PIN
the_DT
company_NN
or_CC
of_PIN
the_DT
group_NN
._.
A_DT
review_NN
of_PIN
the_DT
business_NOMZ
is_VPRT [PASS]
included_VBN
in_PIN
the_DT
directors_NN
report_NN
._.
The_DT
report_NN
of_PIN
the_DT
auditors_NN
on_PIN
the_DT
full_JJ
accounts_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
was_VBD [BEMA]
unqualified_PRED
and_CC
did_VBD
not_XX0
contain_VB
a_DT
statement_NOMZ
made_VBN
under_IN
either_DT
section_NOMZ
237_CD
2_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
accounting_GER
records_NN
or_CC
returns_NN
inadequate_JJ
or_CC
accounts_VPRT
not_XX0
agreeing_VBG [SUAV] [PUBV]
with_PIN
records_NN
or_CC
returns_NN
or_CC
section_NOMZ
237_CD
3_CD
failure_NN
to_TO
obtain_VB
necessary_JJ
information_NOMZ
and_PHC
explanations_NOMZ
._.
For_PIN
further_JJ
information_NOMZ
the_DT
full_JJ
annual_JJ
accounts_NN
and_CC
the_DT
auditors_NN
report_VPRT [PUBV]
on_PIN
those_DEMO
accounts_NN
should_NEMD
be_VB [PASS]
consulted_VBN
._.
Shareholders_NN
have_VPRT
the_DT
right_NN
to_TO
demand_VB [SUAV]
,_,
free_JJ
of_PIN
charge_NN
,_,
a_DT
copy_NN
of_PIN
the_DT
groups_NN
full_JJ
annual_JJ
report_NN
and_PHC
accounts_NN
,_,
which_WDT [SERE]
may_POMD
be_VB [PASS]
obtained_VBN
from_PIN
the_DT
companys_NN
registrars_NN
._.
16_CD
Smith_NN
&_CC
Nephew_NN
2002_CD
Summary_NN
financial_JJ
statement_NOMZ
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
2002_CD
2001_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
million_CD
million_CD
Turnover_NN
Ongoing_VBG [WZPRES]
operations_NOMZ
1,083.7_CD
943.0_CD
Operations_NOMZ
contributed_VBD
to_PIN
the_DT
joint_JJ
venture_NN
35.3_CD
Continuing_VBG
operations_NOMZ
1,083.7_CD
978.3_CD
Discontinued_VBN
operations_NOMZ
26.2_CD
103.4_CD
Group_NN
turnover_NN
1,109.9_CD
1,081.7_CD
Share_NN
of_PIN
joint_JJ
venture_NN
155.0_CD
123.6_CD
1,264.9_CD
1,205.3_CD
Operating_GER
profit_NN
Ongoing_VBG [WZPRES]
operations_NOMZ
:_:
Before_IN
goodwill_NN
amortisation_NOMZ
and_CC
exceptional_JJ
items_NN
196.0_CD
170.8_CD
Goodwill_NN
amortisation_NOMZ
17.5_CD
10.4_CD
Exceptional_JJ
items_NN
29.9_CD
19.3_CD
148.6_CD
141.1_CD
Operations_NOMZ
contributed_VBD
to_PIN
the_DT
joint_JJ
venture_NN
:_:
Before_IN
exceptional_JJ
items_NN
3.6_CD
Exceptional_JJ
items_NN
1.8_CD
Continuing_VBG
operations_NOMZ
148.6_CD
142.9_CD
Discontinued_VBN
operations_NOMZ
2.1_CD
11.1_CD
150.7_CD
154.0_CD
Share_NN
of_PIN
operating_GER
profit_NN
of_PIN
the_DT
joint_JJ
venture_NN
:_:
Before_IN
exceptional_JJ
items_NN
19.6_CD
12.8_CD
Exceptional_JJ
items_NN
2.6_CD
5.0_CD
167.7_CD
161.8_CD
Share_NN
of_PIN
operating_GER
profit_NN
of_PIN
the_DT
associated_VBN
undertaking_GER
4.9_CD
172.6_CD
161.8_CD
Discontinued_VBN
operations_NOMZ
net_JJ
profit_NN
on_PIN
disposals_NN
18.0_CD
49.2_CD
Profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
interest_NN
190.6_CD
211.0_CD
Interest_NN
payable_JJ
12.7_CD
17.4_CD
Profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
177.9_CD
193.6_CD
Taxation_NOMZ
65.8_CD
64.0_CD
Attributable_JJ
profit_NN
for_PIN
the_DT
year_NN
112.1_CD
129.6_CD
Ordinary_NN
dividends_NN
44.6_CD
42.9_CD
Retained_VBN
profit_NN
for_PIN
the_DT
year_NN
67.5_CD
86.7_CD
Basic_JJ
earnings_GER
per_PIN
ordinary_JJ
share_NN
12.11_CD
p_VPRT
14.07_CD
p_JJ
Diluted_JJ
earnings_GER
per_PIN
ordinary_JJ
share_NN
12.02_CD
p_VPRT
13.95_CD
p_JJ
Results_NN
before_IN
goodwill_NN
amortisation_NOMZ
and_CC
exceptional_JJ
items_NN
Profit_NN
before_IN
taxation_NOMZ
209.9_CD
180.9_CD
Adjusted_VBN
basic_JJ
earnings_GER
per_PIN
ordinary_JJ
share_NN
16.02_CD
p_NN
13.96_CD
p_NN
Adjusted_VBN
diluted_JJ
earnings_GER
per_PIN
ordinary_JJ
share_NN
15.89_CD
p_VPRT
13.84_CD
p_JJ
Smith_NN
&_CC
Nephew_NN
2002_CD
17_CD
Summary_NN
financial_JJ
statement_NOMZ
Group_NN
balance_NN
sheet_NN
2002_CD
2001_CD
at_PIN
31_CD
December_NN
2002_CD
million_CD
million_CD
Intangible_JJ
fixed_JJ
assets_NN
317.2_CD
187.8_CD
Tangible_JJ
fixed_JJ
assets_NN
255.8_CD
245.0_CD
Investment_NOMZ
in_PIN
joint_JJ
venture_NN
115.0_CD
114.0_CD
Investment_NOMZ
in_PIN
associated_VBN
undertaking_GER
8.5_CD
Investments_NOMZ
8.2_CD
25.7_CD
704.7_CD
572.5_CD
Stocks_NN
229.5_CD
232.2_CD
Debtors_NN
280.7_CD
266.8_CD
Cash_NN
22.5_CD
26.4_CD
Creditors_NN
315.9_CD
342.8_CD
216.8_CD
182.6_CD
Borrowings_GER
316.1_CD
255.2_CD
Provisions_NN
88.1_CD
95.3_CD
517.3_CD
404.6_CD
Called_VBN
up_RP
share_NN
capital_NN
113.8_CD
113.4_CD
Reserves_NN
403.5_CD
291.2_CD
517.3_CD
404.6_CD
Group_NN
cash_NN
flow_NN
2002_CD
2001_CD
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2002_CD
million_CD
million_CD
Operating_GER
profit_NN
150.7_CD
154.0_CD
Depreciation_NOMZ
,_,
amortisation_NOMZ
and_CC
exceptional_JJ
write-off_PIN
#_#
94.4_CD
60.3_CD
Working_JJ
capital_NN
and_PHC
provisions_NN
35.8_CD
22.4_CD
Net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
activities_NOMZ
209.3_CD
191.9_CD
Capital_NN
expenditure_NN
and_CC
financial_JJ
investment_NOMZ
86.1_CD
72.6_CD
Operating_GER
cash_NN
flow_NN
123.2_CD
119.3_CD
Joint_NN
venture_NN
dividend_NN
3.9_CD
Interest_NN
10.2_CD
16.5_CD
Tax_NN
paid_VBD
52.3_CD
76.2_CD
Dividends_NN
paid_VBD
43.5_CD
42.0_CD
Acquisitions_NOMZ
206.3_CD
69.3_CD
Disposals_NN
71.8_CD
61.7_CD
Joint_NN
venture_NN
formation_NOMZ
5.7_CD
12.6_CD
Issues_NN
of_PIN
ordinary_JJ
share_NN
capital_NN
6.1_CD
9.0_CD
Net_JJ
cash_NN
flow_NN
101.6_CD
1.4_CD
Exchange_NN
adjustments_NOMZ
68.2_CD
5.8_CD
Opening_GER
net_JJ
debt_NN
243.5_CD
236.3_CD
Closing_GER
net_JJ
debt_NN
276.9_CD
243.5_CD
#Includes_NN
goodwill_NN
amortisaton_NN
of_PIN
17.5_CD
m_NN [BEMA]
2001_CD
10.4_CD
m_NN
and_CC
17.5_CD
m_JJ [BEMA]
write-off_PIN
of_PIN
the_DT
groups_NN
equity_NOMZ
investment_NOMZ
in_PIN
Advanced_NN
Tissue_NN
Sciences_NN
,_,
Inc._NN
._.
After_IN
19.3_CD
m_NN [BEMA]
2001_CD
23.5_CD
m_NN [BEMA]
of_PIN
outgoings_GER
on_PIN
rationalisation_NOMZ
,_,
acquisition_NOMZ
integration_NOMZ
and_PHC
divestment_NOMZ
costs_NN
._.
Net_JJ
debt_NN
includes_VPRT
16.7_CD
m_NN [BEMA]
of_PIN
net_JJ
currency_NN
swap_NN
assets_NN
2001_CD
net_JJ
currency_NN
swap_NN
liabilities_NOMZ
of_PIN
14.7_CD
m._FW
18_CD
Smith_NN
&_CC
Nephew_NN
2002_CD
Information_NOMZ
for_PIN
shareholders_NN
Financial_JJ
calendar_NN
Shareview_NN
To_TO
view_VB
information_NOMZ
about_IN
your_SPP2
shareholdings_GER
on_PIN
the_DT
internet_NN
,_,
register_NN
at_PIN
www_NN
._.
Smith_NN
&_CC
Nephew_NN
2002_CD
19_CD
Group_NN
five_CD
year_NN
summary_NN
2002 2001 2000 1999_CD
#_#
1998_CD
#_#
Profit_NN
and_PHC
loss_NN
account_NN
million_CD
million_CD
million_CD
million_CD
million_CD
Turnover_NN
Continuing_VBG [WZPRES]
operations_NOMZ
1,083.7_CD
978.3_CD
911.5_CD
799.9_CD
713.6_CD
Discontinued_VBN
operations_NOMZ
26.2_CD
103.4_CD
223.2_CD
320.0_CD
339.8_CD
Group_NN
turnover_NN
1,109.9_CD
1,081.7_CD
1,134.7_CD
1,119.9_CD
1,053.4_CD
Share_NN
of_PIN
joint_JJ
venture_NN
155.0_CD
123.6_CD
1,264.9_CD
1,205.3_CD
1,134.7_CD
1,119.9_CD
1,053.4_CD
Operating_GER
profit_NN
Continuing_VBG [WZPRES]
operations_NOMZ
:_:
Before_IN
goodwill_NN
amortisation_NOMZ
and_CC
exceptional_JJ
items_NN
196.0_CD
174.4_CD
156.9_CD
122.7_CD
106.5_CD
Goodwill_NN
amortisation_NOMZ
17.5_CD
10.4_CD
6.9_CD
1.8_CD
0.3_CD
Exceptional_JJ
items_NN
29.9_CD
21.1_CD
12.4_CD
40.1_CD
15.9_CD
Discontinued_VBN
operations_NOMZ
:_:
Before_IN
exceptional_JJ
items_NN
2.1_CD
11.1_CD
29.0_CD
46.6_CD
47.9_CD
Exceptional_JJ
items_NN
3.9_CD
11.6_CD
2.0_CD
150.7_CD
154.0_CD
162.7_CD
115.8_CD
136.2_CD
Share_NN
of_PIN
operating_GER
profit_NN
of_PIN
the_DT
joint_JJ
venture_NN
:_:
Before_IN
exceptional_JJ
items_NN
19.6_CD
12.8_CD
Exceptional_JJ
items_NN
2.6_CD
5.0_CD
167.7_CD
161.8_CD
162.7_CD
115.8_CD
136.2_CD
Share_NN
of_PIN
operating_GER
profit_NN
of_PIN
the_DT
associated_VBN
undertaking_GER
4.9_CD
172.6_CD
161.8_CD
162.7_CD
115.8_CD
136.2_CD
Profit_NN
on_PIN
disposals_NN
18.0_CD
49.2_CD
109.5_CD
62.9_CD
Profit_NN
before_IN
interest_NN
190.6_CD
211.0_CD
272.2_CD
178.7_CD
136.2_CD
Interest_NN
payable_JJ
receivable_JJ
12.7_CD
17.4_CD
7.0_CD
3.4_CD
1.7_CD
Profit_NN
before_IN
taxation_NOMZ
177.9_CD
193.6_CD
265.2_CD
182.1_CD
134.5_CD
Taxation_NOMZ
65.8_CD
64.0_CD
57.7_CD
77.3_CD
40.8_CD
Profit_NN
after_IN
taxation_NOMZ
112.1_CD
129.6_CD
207.5_CD
104.8_CD
93.7_CD
Ordinary_NN
dividends_NN
44.6_CD
42.9_CD
41.3_CD
72.5_CD
69.2_CD
Special_JJ
dividend_NN
415.6_CD
Retained_VBN
profit_NN
deficit_NN
67.5_CD
86.7_CD
249.4_CD
32.3_CD
24.5_CD
Basic_JJ
earnings_GER
per_PIN
ordinary_JJ
share_NN
12.11_CD
p_VPRT
14.07_CD
p_JJ
20.07_CD
p_NN
9.39_CD
p_VPRT
8.42_CD
p_JJ
Diluted_JJ
earnings_GER
per_PIN
ordinary_JJ
share_NN
12.02_CD
p_VPRT
13.95_CD
p_JJ
19.95_CD
p_NN
9.37_CD
p_NN
8.40_CD
p_NN
Dividends_NN
per_PIN
ordinary_JJ
share_NN
4.80_CD
p_VPRT
4.65_CD
p_JJ
4.50_CD
p_NN
6.50_CD
p_NN
6.20_CD
p_NN
Results_NN
before_IN
goodwill_NN
amortisation_NOMZ
and_CC
exceptional_JJ
items_NN
:_:
Profit_NN
before_IN
taxation_NOMZ
209.9_CD
180.9_CD
178.9_CD
172.7_CD
152.7_CD
Adjusted_VBN
earnings_GER
per_PIN
ordinary_JJ
share_NN
16.02_CD
p_NN
13.96_CD
p_NN
12.19_CD
p_VPRT
10.88_CD
p_JJ
9.61_CD
p_NN
Adjusted_VBN
diluted_JJ
earnings_GER
per_PIN
ordinary_JJ
share_NN
15.89_CD
p_VPRT
13.84_CD
p_JJ
12.12_CD
p_NN
10.85_CD
p_VPRT
9.60_CD
p_JJ
Operating_GER
profit_NN
before_IN
goodwill_NN
amortisation_NOMZ
and_CC
17.8_CD
%_NN
17.1_CD
%_NN
16.4_CD
%_NN
15.1_CD
%_NN
14.7_CD
%_NN
exceptional_JJ
items_NN
to_PIN
group_NN
sales_NN
Research_NN
and_PHC
development_NOMZ
costs_NN
to_PIN
group_NN
sales_NN
5.5_CD
%_NN
4.7_CD
%_NN
4.0_CD
%_NN
4.0_CD
%_NN
4.1_CD
%_NN
Capital_NN
investment_NOMZ
including_VBG [WZPRES]
intangibles_NN
to_PIN
group_NN
sales_NN
7.7_CD
%_NN
6.9_CD
%_NN
5.6_CD
%_NN
5.8_CD
%_NN
6.6_CD
%_NN
#_#
1999_CD
and_CC
1998_CD
have_VPRT [PEAS]
not_XX0
been_VBN [PASS]
restated_VBN
for_PIN
FRS_NN
19_CD
._.
You_SPP2
have_VPRT
access_NN
to_PIN
more_EMPH
information_NOMZ
from_PIN
the_DT
following_JJ
sources_NN
:_:
Board_NN
Group_NN
Executive_NN
Committee_NN
biographies_NN
For_PIN
further_JJ
biographies_NN
,_,
visit_NN
:_:
www_NN
._.
html_NN
You_SPP2
are_VPRT
here_RB
:_:
Report_NN
to_PIN
Shareholders_NN
and_PHC
Summary_NN
Financial_NN
Statement_NOMZ
Contents_NN
Financial_NN
highlights_VPRT
Chairmans_NN
statement_NOMZ
Chief_NN
Executives_NN
statement_NOMZ
Board_NN
&_CC
Group_NN
Executive_NN
Committee_NN
Corporate_NN
social_JJ
responsibility_NOMZ
Corporate_JJ
governance_NN
Summary_NN
remuneration_NOMZ
report_NN
Auditors_NN
statement_NOMZ
Summary_NN
financial_JJ
statement_NOMZ
Annual_JJ
Report_NN
and_PHC
Accounts_NN
Information_NOMZ
for_PIN
shareholders_NN
For_PIN
detailed_JJ
financial_JJ
information_NOMZ
Group_NN
five_CD
year_NN
summary_NN
you_SPP2
can_POMD
request_VB [SUAV]
a_DT
full_JJ
printed_VBN
Annual_JJ
Report_NN
and_PHC
Accounts_NN
or_CC
visit_NN
:_:
www_NN
._.
com_NN
investors_NN
annualreport2002_JJ
Available_JJ
as_IN
a_DT
printed_VBN
document_NOMZ
or_CC
online_NN
at_PIN
:_:
www_NN
._.
